Human Colipase (CLPS): A Comprehensive Review

Introduction and Summary

Colipase (gene symbol: CLPS; UniProt: P04118) is a small, essential protein cofactor that enables the efficient hydrolysis of dietary triglycerides by pancreatic lipase in the human duodenum. The protein is encoded by the CLPS gene located on chromosome 6p21.31 and is expressed exclusively in the pancreas [sims-1992-gene-structure-abstract]. Colipase belongs to a family of cysteine-rich proteins characterized by a distinctive structural fold stabilized by five disulfide bonds [egloff-1995-crystallographic-abstract].

The primary biological function of colipase is to counteract the inhibitory effect of bile salts on pancreatic triglyceride lipase (PTL), allowing the enzyme to remain anchored at the lipid-water interface where it catalyzes fat digestion [borgstrom-1975-interactions-abstract]. Without colipase, bile salts would wash lipase away from its substrate, effectively halting triglyceride hydrolysis in the physiological environment of the small intestine [chapus-1988-minireview-abstract]. The colipase-PTL system accounts for approximately 60% of dietary triglyceride hydrolysis in adult humans, making it essential for normal fat absorption and nutrition [lowe-1997-structure-function-abstract].

Colipase is secreted from pancreatic acinar cells as an inactive precursor, procolipase, which is activated in the intestinal lumen by trypsin-mediated cleavage. This activation releases a five-amino-acid N-terminal peptide called enterostatin, which has been shown to function as a satiety signal that specifically suppresses dietary fat intake [okada-1991-enterostatin-fat-intake-abstract]. Thus, the CLPS gene product has dual functions: the mature colipase enables fat digestion while the enterostatin peptide may provide feedback regulation of fat consumption.

Biochemical Function and Mechanism

The Problem: Bile Salt Inhibition of Lipase

Dietary fat digestion in the small intestine presents a unique biochemical challenge. Pancreatic lipase, the primary enzyme responsible for hydrolyzing triglycerides into absorbable monoglycerides and free fatty acids, must function at lipid-water interfaces in the presence of bile salts [lowe-1997-structure-function-abstract]. Bile salts, secreted from the liver and concentrated in the gallbladder, are amphipathic molecules essential for emulsifying dietary fats into micelles that increase the surface area available for enzymatic attack.

However, at concentrations above their critical micellar concentration (CMC), bile salts strongly inhibit pancreatic lipase activity [borgstrom-1975-interactions-abstract]. This inhibition occurs through a mechanism whereby bile salts displace lipase from hydrophobic substrate interfaces. The observation of this paradox—that bile salts are both necessary for fat digestion yet inhibitory to the key digestive enzyme—led to the discovery of colipase in 1963 by the laboratory of Professor Borgström in Lund, Sweden [chapus-1988-minireview-abstract].

Colipase as a Cofactor

Colipase functions by providing a high-affinity binding site for lipase at the bile salt-covered lipid interface [borgstrom-1975-interactions-abstract]. The protein binds to the non-catalytic C-terminal domain of pancreatic lipase with a 1:1 stoichiometry, forming a stable complex [vantilbeurgh-1999-colipase-structure-abstract]. This interaction stabilizes lipase in an active conformation and considerably increases the overall hydrophobic binding site available for substrate interaction [egloff-1995-crystallographic-abstract].

The mechanism of colipase action involves multiple effects. First, colipase anchors the lipase to the substrate interface, counteracting the displacement effect of bile salts. Second, colipase stabilizes the "open" conformation of the lipase lid domain, a 23-amino-acid surface loop that must move away from the active site to allow substrate access [yang-2000-open-lid-abstract]. Third, colipase creates a more favorable microenvironment at the interface by packing more efficiently with substrates and products of lipolysis than with phosphatidylcholine, thereby concentrating reactants near the enzyme [vantilbeurgh-1999-colipase-structure-abstract].

At physiological pH (6-7), colipase fully restores lipase activity that would otherwise be completely inhibited by bile salts, and actually shifts the pH optimum of the enzyme from 8-9 (in the absence of bile salts) to 6-7 (the normal duodenal environment) [borgstrom-1975-interactions-abstract].

Substrate Specificity

Colipase enables pancreatic lipase to efficiently hydrolyze dietary triglycerides of varying chain lengths. The lipase preferentially cleaves ester bonds at the sn-1 and sn-3 positions of triglycerides, producing 2-monoacylglycerol and free fatty acids as the primary products [lowe-1997-structure-function-abstract]. The colipase-lipase system operates on long-chain triglycerides (the predominant form in the diet), medium-chain triglycerides, and short-chain triglycerides, though the efficiency varies somewhat with chain length [dsilva-2007-polymorphism-abstract].

Structural Biology

Protein Structure

Colipase is a small protein of approximately 10 kDa (90 amino acids in mature form) with a distinctive three-dimensional structure that has been determined by both X-ray crystallography and NMR spectroscopy [egloff-1995-crystallographic-abstract][vantilbeurgh-1999-colipase-structure-abstract][breg-1995-procolipase-NMR-abstract]. The protein adopts a flat, finger-like shape with dimensions of approximately 25 × 30 × 35 Å. Secondary structure analysis reveals that colipase contains approximately 5% alpha-helix (residues 39-44), 25% beta-sheet organized into three separate regions (residues 7-11, 49-57, and 77-85), and eight beta-turns comprising approximately 32% of the polypeptide [breg-1995-procolipase-NMR-abstract]. Importantly, the solution structure determined by NMR is nearly identical to the crystal structure, confirming that the crystallographic conformation represents the native state of the protein [breg-1995-procolipase-NMR-abstract].

The structure is stabilized primarily by an extended network of five disulfide bonds connecting ten conserved cysteine residues at positions 34-45, 40-56, 44-78, 66-86, and 80-104 [egloff-1995-crystallographic-abstract]. This disulfide network runs throughout the molecule, reticulating four protruding finger-like loops. The surface of colipase is divided into a hydrophilic region that interacts with lipase and a more hydrophobic region formed by the tips of the finger loops that contacts lipid interfaces [egloff-1995-crystallographic-abstract].

Lipase-Colipase Complex

The crystal structure of the pancreatic lipase-colipase complex has been solved at high resolution (2.46 Å), providing detailed insight into their interaction [egloff-1995-246A-structure-abstract]. Pancreatic lipase itself is a 50 kDa single-chain glycoprotein of 449 amino acids consisting of two structural domains: an N-terminal domain (336 residues) containing the catalytic site, and a C-terminal domain (113 residues) devoted to colipase binding [lowe-1997-structure-function-abstract].

The N-terminal catalytic domain has a typical alpha/beta hydrolase fold topology and contains the catalytic triad of Ser153, His264, and Asp177 [lowe-1997-structure-function-abstract]. The C-terminal domain has a beta-sheet sandwich topology and provides the primary binding site for colipase [vantilbeurgh-1999-colipase-structure-abstract].

The interaction between colipase and the C-terminal domain of lipase is stabilized by eight hydrogen bonds and approximately 80 van der Waals contacts [egloff-1995-crystallographic-abstract]. However, when lipase binds to a lipid interface and the lid domain opens, three additional hydrogen bonds and approximately 28 more van der Waals contacts are formed between colipase and the newly positioned lid [egloff-1995-crystallographic-abstract]. This explains the higher apparent affinity of the lipase-colipase complex observed in the presence of lipid/water interfaces.

The Lid Domain and Interfacial Activation

A key structural feature of pancreatic lipase is the "lid domain," a 23-amino-acid surface loop that overlies the active site in the closed (inactive) conformation [yang-2000-open-lid-abstract]. Upon contact with lipid interfaces or amphiphilic molecules, this lid undergoes a dramatic conformational change, moving away from the active site to create access for substrate binding [lowe-1997-structure-function-abstract].

Colipase plays a critical role in stabilizing this open conformation. In the active complex, colipase is held in a grip between the N-terminal and C-terminal domains of lipase, with interactions extending to the repositioned lid [vantilbeurgh-1999-colipase-structure-abstract]. Studies using lid-swap chimeras between different lipases demonstrated that specific residues in the lid (particularly Arg257 and Asp258) are essential for proper colipase interaction and enzyme function [yang-2000-open-lid-abstract].

Bile Salt Binding Site

High-resolution NMR studies have characterized the bile salt binding properties of colipase [wieloch-1979-NMR-bile-salt-abstract]. These experiments revealed that all three tyrosine residues and one histidine residue in porcine colipase are affected by taurodeoxycholate (bile salt) binding, indicating that the bile salt molecules bind near these residues in a hydrophobic region on the colipase surface [wieloch-1979-NMR-bile-salt-abstract]. This binding interaction is essential for colipase's ability to function at bile salt-covered lipid interfaces.

Evolutionary Conservation and Structural Homology

The colipase fold is highly conserved and has been identified in a diverse range of proteins beyond pancreatic colipases [vantilbeurgh-1999-colipase-structure-abstract]. A particularly interesting structural analogy exists between colipase and a domain in the Dickkopf (Dkk) family of Wnt signaling antagonists. The C-terminal cysteine-rich domain of Dickkopf proteins shares the same disulfide-bonding pattern and overall fold as colipase, suggesting an ancient evolutionary relationship [vantilbeurgh-1999-colipase-structure-abstract]. Whether this structural similarity implies a conserved function in lipid interaction remains to be clarified.

The colipase fold has also been identified in several animal toxins, including mamba intestinal toxin 1 (MIT1) from the black mamba snake, which shows remarkably high structural homology with colipase (RMSD of 1.3 Å for more than 60 residues) despite limited sequence similarity [vantilbeurgh-1999-colipase-structure-abstract]. MIT1 and colipase share identical disulfide patterns and similar secondary structure motifs, representing a striking example of structural conservation across functionally diverse proteins. Additionally, related structural folds have been found in funnel web spider toxins.

Cellular Localization and Secretion

Gene Structure and Expression

The human CLPS gene is located on chromosome 6p21.31, spanning approximately 2.3 kb of genomic DNA organized into three exons [sims-1992-gene-structure-abstract][davis-1991-chromosome-mapping-abstract]. The 5'-flanking region contains characteristic regulatory elements including a TATA box, a GC box, and a 28-bp region with homology to the rat pancreatic-specific enhancer [sims-1992-gene-structure-abstract]. This enhancer region binds specific nuclear factors and directs tissue-specific expression exclusively in pancreatic acinar cells, as demonstrated by transfection experiments where the promoter was active in AR42-J rat pancreatic acinar cells but inactive in hepatic (HEPG2), muscle (C2C12), and kidney (COS-1) cell lines [sims-1992-gene-structure-abstract].

Biosynthesis and Secretion

Colipase is synthesized in pancreatic acinar cells as a precursor protein (preprocolipase) of 112 amino acids [lowe-1997-structure-function-abstract]. The initial translation product includes a 17-residue signal peptide that directs the protein into the secretory pathway. Following signal peptide cleavage, the resulting procolipase (95 amino acids) is packaged into zymogen granules along with other digestive enzymes including pancreatic lipase, trypsinogen, and various proteases.

The ratio of procolipase to pancreatic lipase in pancreatic secretions is approximately 1:1, ensuring stoichiometric availability of the cofactor [lowe-1997-structure-function-abstract]. Upon stimulation by cholecystokinin (CCK)—released from intestinal I-cells in response to dietary fat—or by vagal acetylcholine release, pancreatic acinar cells undergo calcium-mediated exocytosis of zymogen granule contents into the pancreatic ductal system.

Activation in the Intestinal Lumen

Procolipase remains in its inactive precursor form until reaching the duodenum, where it is activated by trypsin-catalyzed cleavage of a five-amino-acid N-terminal peptide (the activation peptide) [okada-1991-enterostatin-fat-intake-abstract]. This cleavage generates two products: the mature, active colipase (90 amino acids) and enterostatin.

Importantly, procolipase and mature colipase have similar abilities to interact with pancreatic lipase and restore its activity, suggesting that the primary purpose of the trypsin-catalyzed activation step is to release enterostatin rather than to regulate colipase function per se [dsilva-2007-polymorphism-abstract].

Role in Lipid Digestion Pathway

The Lipolytic Triad

Dietary fat digestion in the mammalian small intestine is accomplished by a highly efficient trio of factors: pancreatic lipase, colipase, and bile salts [chapus-1988-minireview-abstract]. These three components work synergistically to hydrolyze dietary triglycerides in an environment where other lipases would fail [lowe-1997-structure-function-abstract].

The process begins with the emulsification of dietary fat by bile salts and mechanical mixing in the duodenum, creating a bile salt-covered lipid-water interface. Colipase first adsorbs to this interface through its hydrophobic finger tips, then recruits and anchors pancreatic lipase [borgstrom-1975-interactions-abstract]. The resulting colipase-lipase complex efficiently catalyzes the stepwise hydrolysis of triglycerides to 2-monoacylglycerol and free fatty acids, which are then absorbed by enterocytes.

Evidence from Knockout Studies

The essential role of colipase in fat digestion has been confirmed through studies of colipase-deficient (Clps-/-) mice. These animals exhibit decreased postnatal survival and weight gain, steatorrhea (fatty stools indicating fat malabsorption) on high-fat diets, and reduced body fat compared to wild-type littermates [dsilva-2007-polymorphism-abstract]. Interestingly, the fat malabsorption phenotype is more severe in colipase-deficient mice than in pancreatic lipase-deficient mice, likely because colipase also stimulates the activity of pancreatic lipase-related protein 2 (PLRP2), which contributes to triglyceride digestion especially in nursing pups.

Enterostatin as a Satiety Signal

The activation peptide released from procolipase, enterostatin, has been demonstrated to function as a satiety signal that specifically reduces dietary fat intake [okada-1991-enterostatin-fat-intake-abstract]. In rats, intracerebroventricular injection of enterostatin (sequence VPDPR in most species, though APGPR in humans) selectively decreased consumption of high-fat diet by 45% while leaving low-fat diet intake unchanged [okada-1991-enterostatin-fat-intake-abstract].

Because procolipase secretion increases during high-fat feeding, enterostatin has been proposed as a feedback regulator connecting fat digestion to central appetite control [okada-1991-enterostatin-fat-intake-abstract]. However, studies in enterostatin-deficient mice (procolipase knockouts) suggest that enterostatin is not critically required for food intake regulation, as other compensatory pathways may exist. Nonetheless, enterostatin appears to have developmental effects on survival of newborns and alters cholesterol metabolism in mice.

Clinical Significance

Association with Type 2 Diabetes

A functional polymorphism in the CLPS gene (Arg109Cys in the preproprotein, corresponding to Arg92Cys in mature colipase) has been associated with increased risk of type 2 diabetes mellitus in two independent Caucasian populations [lindner-2005-diabetes-association-abstract]. In these studies, carriers of the Arg/Cys genotype (found in 2-3% of the population) had 3.75 to 4.86-fold increased odds of developing type 2 diabetes compared to non-carriers [lindner-2005-diabetes-association-abstract].

Functional characterization of this variant revealed that Cys92 colipase has decreased function specifically against long-chain triglycerides (only 50% of wild-type activity), while retaining full activity against short- and medium-chain triglycerides [dsilva-2007-polymorphism-abstract]. Furthermore, the variant protein is unstable and loses activity upon storage at 4°C due to oxidation of the extra cysteine residue, which disrupts the disulfide bond network essential for proper protein folding [dsilva-2007-polymorphism-abstract].

The mechanism linking impaired colipase function to diabetes risk is not fully established, but may involve altered fat absorption, changed postprandial lipid metabolism, or effects on enterostatin-mediated signaling. Additional genetic studies have shown that CLPS variability associates with altered insulin secretory function in non-diabetic humans, supporting a role for this gene in metabolic regulation beyond simple fat digestion [lindner-2005-diabetes-association-abstract].

Pancreatic Insufficiency

Deficiency of pancreatic enzymes including lipase and colipase occurs in various conditions affecting the exocrine pancreas, including cystic fibrosis, chronic pancreatitis, and pancreatic cancer. In these conditions, enzyme replacement therapy is typically administered with meals to maintain fat absorption. The colipase-lipase complex provides the rationale for including both components in enzyme replacement preparations to maximize efficacy in the presence of endogenous bile salts.

Open Questions

Several important questions remain regarding colipase biology and function:

1. Enterostatin signaling mechanism: The precise molecular pathway by which enterostatin suppresses fat intake—including its receptor, signaling cascade, and integration with other satiety signals—remains incompletely characterized. Understanding this pathway could have implications for obesity treatment.

2. Dickkopf-colipase evolutionary relationship: The functional significance of the structural homology between colipase and the Dickkopf family of Wnt antagonists remains unclear. Does the colipase fold in Dickkopf proteins serve a lipid-binding function, or has the structure been co-opted for different purposes?

3. Therapeutic potential of colipase variants: Could engineered colipase variants with enhanced stability or function be developed for improved enzyme replacement therapy in pancreatic insufficiency?

4. Diabetes mechanism: The molecular mechanism linking the Arg92Cys colipase polymorphism to type 2 diabetes risk warrants further investigation. Is the effect mediated through altered fat absorption, changes in enterostatin release, or other metabolic pathways?

5. Regulation of expression: The factors controlling CLPS gene expression during development and in response to dietary changes are not fully understood. How does the pancreas coordinate expression of lipase and colipase to maintain their 1:1 ratio?

6. Colipase-like proteins: The human genome contains a related gene, CLPSL1 (colipase-like 1), located on chromosome 6p21.31, encoding a protein with predicted enzyme activator activity and annotations suggesting roles in digestion and response to food. However, the precise function of CLPSL1 remains uncharacterized—it shows only ~30% sequence identity to orthologs in mouse and rat. Does this protein serve as a functional paralog of CLPS with tissue-specific or developmental roles in lipid metabolism?

7. Computational advances: Recent computational studies using AlphaFold and molecular dynamics simulations are revealing new details about lipase-colipase-fatty acid interactions, including the regulatory roles of calcium ions. How can these computational insights be translated into therapeutic applications for pancreatic diseases?

References

• borgstrom-1975-interactions-abstract: Borgström B. On the interactions between pancreatic lipase and colipase and the substrate, and the importance of bile salts. J Lipid Res. 1975 Nov;16(6):411-7. PMID: 446.

• chapus-1988-minireview-abstract: Chapus C, Rovery M, Sarda L, Verger R. Minireview on pancreatic lipase and colipase. Biochimie. 1988 Sep;70(9):1223-34. PMID: 3147715. DOI: 10.1016/0300-9084(88)90188-5.

• davis-1991-chromosome-mapping-abstract: Davis RC, Xia YR, Mohandas T, Schotz MC, Lusis AJ. Assignment of the human pancreatic colipase gene to chromosome 6p21.1 to pter. Genomics. 1991 May;10(1):262-5. PMID: 2045105. DOI: 10.1016/0888-7543(91)90511-c.

• dsilva-2007-polymorphism-abstract: D'Silva S, Xiao X, Lowe ME. A polymorphism in the gene encoding procolipase produces a colipase, Arg92Cys, with decreased function against long-chain triglycerides. J Lipid Res. 2007 Nov;48(11):2478-84. PMID: 17715423. PMCID: PMC3684974. DOI: 10.1194/jlr.M700371-JLR200.

• egloff-1995-crystallographic-abstract: Egloff MP, Sarda L, Verger R, Cambillau C, van Tilbeurgh H. Crystallographic study of the structure of colipase and of the interaction with pancreatic lipase. Protein Sci. 1995 Jan;4(1):44-57. PMID: 7773176. DOI: 10.1002/pro.5560040107.

• egloff-1995-246A-structure-abstract: Egloff MP, Marguet F, Buono G, Verger R, Cambillau C, van Tilbeurgh H. The 2.46 A resolution structure of the pancreatic lipase-colipase complex inhibited by a C11 alkyl phosphonate. Biochemistry. 1995 Mar 7;34(9):2751-62. PMID: 7893686. DOI: 10.1021/bi00009a003. PDB: 1LPB.

• lindner-2005-diabetes-association-abstract: Lindner I, Helwig U, Rubin D, Li Y, Fisher E, Boeing H, Möhlig M, Spranger J, Pfeiffer A, Hampe J, Schreiber S, Döring F, Schrezenmeir J. Putative association between a new polymorphism in exon 3 (Arg109Cys) of the pancreatic colipase gene and type 2 diabetes mellitus in two independent Caucasian study populations. Mol Nutr Food Res. 2005 Oct;49(10):972-6. PMID: 16189801. DOI: 10.1002/mnfr.200500087.

• lowe-1997-structure-function-abstract: Lowe ME. Structure and function of pancreatic lipase and colipase. Annu Rev Nutr. 1997;17:141-58. PMID: 9240923. DOI: 10.1146/annurev.nutr.17.1.141.

• okada-1991-enterostatin-fat-intake-abstract: Okada S, York DA, Bray GA, Erlanson-Albertsson C. Enterostatin (Val-Pro-Asp-Pro-Arg), the activation peptide of procolipase, selectively reduces fat intake. Physiol Behav. 1991 Jun;49(6):1185-9. PMID: 1896500. DOI: 10.1016/0031-9384(91)90349-s.

• sims-1992-gene-structure-abstract: Sims HF, Lowe ME. The human colipase gene: isolation, chromosomal location, and tissue-specific expression. Biochemistry. 1992 Aug 11;31(31):7120-5. PMID: 1643046. DOI: 10.1021/bi00146a013.

• vantilbeurgh-1999-colipase-structure-abstract: van Tilbeurgh H, Bezzine S, Cambillau C, Verger R, Carrière F. Colipase: structure and interaction with pancreatic lipase. Biochim Biophys Acta. 1999 Nov 23;1441(2-3):173-84. PMID: 10570245. DOI: 10.1016/s1388-1981(99)00149-3.

• wieloch-1979-NMR-bile-salt-abstract: Wieloch T, Borgström B, Falk KE, Forsén S. High-resolution proton magnetic resonance study of porcine colipase and its interactions with taurodeoxycholate. Biochemistry. 1979 Apr 17;18(8):1622-8. PMID: 570855. DOI: 10.1021/bi00576a003.

• breg-1995-procolipase-NMR-abstract: Breg JN, et al. Solution Structure of Porcine Pancreatic Procolipase as Determined from 1H Homonuclear Two-Dimensional and Three-Dimensional NMR. Eur J Biochem. 1995;229:663-672. PDB: 1PCO.

• yang-2000-open-lid-abstract: Yang Y, Lowe ME. The open lid mediates pancreatic lipase function. J Lipid Res. 2000 Jan;41(1):48-57. PMID: 10627501.

Citations

1. borgstrom-1975-interactions-abstract.md
2. breg-1995-procolipase-NMR-abstract.md
3. chapus-1988-minireview-abstract.md
4. davis-1991-chromosome-mapping-abstract.md
5. dsilva-2007-polymorphism-abstract.md
6. egloff-1995-246A-structure-abstract.md
7. egloff-1995-crystallographic-abstract.md
8. lindner-2005-diabetes-association-abstract.md
9. lowe-1997-structure-function-abstract.md
10. okada-1991-enterostatin-fat-intake-abstract.md
11. sims-1992-gene-structure-abstract.md
12. vantilbeurgh-1999-colipase-structure-abstract.md
13. wieloch-1979-NMR-bile-salt-abstract.md
14. yang-2000-open-lid-abstract.md

The research report should be a detailed narrative explaining the function, biological processes, and localization of the gene product. Citations should be given for all claims.

You should prioritize authoritative reviews and primary scientific literature when conducting research. You can supplement
this with annotations you find in gene/protein databases, but these can be outdated or inaccurate.

We are specifically interested in the primary function of the gene - for enzymes, what reaction is catalyzed, and what is the substrate specificity? For transporters, what is the substrate? For structural proteins or adapters, what is the broader structural role? For signaling molecules, what is the role in the pathway.

We are interested in where in or outside the cell the gene product carries out its function.

We are also interested in the signaling or biochemical pathways in which the gene functions. We are less interested in broad pleiotropic effects, except where these elucidate the precise role.

Include evidence where possible. We are interested in both experimental evidence as well as inference from structure, evolution, or bioinformatic analysis. Precise studies should be prioritized over high-throughput, where available.

Plan overview
We verified the human target identity (CLPS; UniProt P04118) and collected mechanistic, structural, physiological, and recent omics evidence. We synthesized key concepts, recent developments (emphasizing 2023–2024), applications, and quantitative data, and we compiled a summary artifact.

Executive summary
CLPS encodes human pancreatic colipase, a small secreted protein cofactor required for optimal pancreatic triglyceride lipase (PNLIP/PTL) activity at the oil–water interface in the presence of bile salts during intestinal fat digestion. Colipase binds the C-terminal domain of PTL, stabilizes the open-lid conformation, and anchors the catalytic domain to bile salt–lined lipid micelles, enabling interfacial activation and efficient hydrolysis of dietary triacylglycerols. CLPS is expressed in pancreatic acinar cells and secreted with PTL into the duodenum; its gene maps to human chromosome 6p21.1–pter. A 2024 large-scale pQTL/GWAS colocalization study reported that plasma CLPS levels colocalize at an RNLS-associated type 1 diabetes locus, supporting an exocrine pancreas contribution to T1D biology, though this is a preprint. Selected quantitative estimates indicate PTL with colipase accounts for roughly three-quarters of luminal triglyceride hydrolysis. (lim2022lipasesitsnot pages 2-4, lim2022lipasesitsnot pages 4-5, lowe2002thetriglyceridelipases pages 1-2, lowe2002thetriglyceridelipases pages 2-3, lowe2002thetriglyceridelipases pages 7-8, davis1991assignmentofthe pages 2-3, elgamal2024circulatingpancreaticenzyme pages 1-4)

Key concepts and definitions
- Identity and family/domain context. CLPS encodes human pancreatic colipase (colipase family). Colipase is a small, secreted, heat-stable protein cofactor (~10–12 kDa) with a flattened, disulfide-stabilized three-finger fold that interfaces with the noncatalytic C-terminal domain of pancreatic triglyceride lipase (PTL/PNLIP) (Annual Review of Nutrition, 1997; Journal of Lipid Research, 2002). These features align with the colipase family annotation and domain organization noted for UniProt P04118. URL: https://doi.org/10.1146/annurev.nutr.17.1.141 (1997-07); https://doi.org/10.1194/jlr.r200012-jlr200 (2002-12) (lowe1997structureandfunction pages 3-6, lowe2002thetriglyceridelipases pages 1-2, lowe2002thetriglyceridelipases pages 7-8)
- Primary biochemical role. Colipase is essential for optimal PTL activity at physiological bile salt concentrations because bile salts inhibit PTL adsorption to the lipid interface. Colipase forms a specific 1:1 complex with PTL, reverses bile salt inhibition, and enables interfacial activation so that PTL hydrolyzes triacylglycerol to diacylglycerol, monoacylglycerol, and free fatty acids for micellar uptake (Biochemistry, 1999; J Lipid Res, 2002; Am J Vet Res, 2022). URLs: https://doi.org/10.1021/bi982601x (1999-04); https://doi.org/10.1194/jlr.r200012-jlr200 (2002-12); https://doi.org/10.2460/ajvr.22.03.0048 (2022-08) (bezzine1999humanpancreaticlipase pages 1-2, lowe2002thetriglyceridelipases pages 1-2, lim2022lipasesitsnot pages 2-4, lim2022lipasesitsnot pages 4-5)
- Substrate and localization context. The PTL–colipase complex acts at the oil–water interface of dietary lipid droplets and bile salt micelles in the intestinal lumen; products join mixed micelles for enterocyte absorption and chylomicron assembly (Ann Rev Nutr, 1997; Am J Vet Res, 2022). URLs: https://doi.org/10.1146/annurev.nutr.17.1.141 (1997-07); https://doi.org/10.2460/ajvr.22.03.0048 (2022-08) (lowe1997structureandfunction pages 3-6, lim2022lipasesitsnot pages 2-4)
- Proprotein processing and enterostatin. Colipase is synthesized as procolipase and activated in the duodenum by trypsin cleavage, which releases the N‑terminal pentapeptide enterostatin. Enterostatin has been detected in the gut and circulation in animal studies and reduces voluntary fat intake in rodents, consistent with a signaling role, though human evidence remains limited (Ann Rev Nutr, 1997). URL: https://doi.org/10.1146/annurev.nutr.17.1.141 (1997-07) (lowe1997structureandfunction pages 3-6)

Mechanism and structural features
- Lipase–colipase complex and lid dynamics. PTL is a two-domain enzyme: an N‑terminal α/β-hydrolase fold harboring the catalytic triad and a C‑terminal β‑sandwich domain that binds colipase. In solution, a mobile lid covers the active site; at the interface and with colipase, the lid opens, forming a continuous hydrophobic plateau with the PTL “5‑loop” and colipase finger tips to engage the lipid surface (Am J Vet Res, 2022; J Lipid Res, 2002). URLs: https://doi.org/10.2460/ajvr.22.03.0048 (2022-08); https://doi.org/10.1194/jlr.r200012-jlr200 (2002-12) (lim2022lipasesitsnot pages 2-4, lowe2002thetriglyceridelipases pages 7-8)
- Binding surfaces and key residues. Mutational and structural work implicates colipase residues (e.g., Glu45, Glu64, Arg65, Asn89) contacting PTL residues (e.g., Asn366, Gln369, Lys400), while PTL’s hydrophobic 5‑loop (residues ~405–414) is critical for interfacial binding; antibodies against the 5‑loop abolish interfacial activity (J Lipid Res, 2002; Biochemistry, 1999). URLs: https://doi.org/10.1194/jlr.r200012-jlr200 (2002-12); https://doi.org/10.1021/bi982601x (1999-04) (lowe2002thetriglyceridelipases pages 7-8, bezzine1999humanpancreaticlipase pages 1-2)
- Bile salts and interfacial activation. Bile salts assemble on lipid droplets forming micelles that both inhibit PTL adsorption and, when colipase is present, provide the platform for the active PTL–colipase complex; colipase anchors PTL to the micellar surface and stabilizes the open active conformation (Am J Vet Res, 2022; Biochemistry, 1999). URLs: https://doi.org/10.2460/ajvr.22.03.0048 (2022-08); https://doi.org/10.1021/bi982601x (1999-04) (lim2022lipasesitsnot pages 2-4, bezzine1999humanpancreaticlipase pages 1-2)

Cellular and tissue context; pathway placement
- Expression, secretion, and localization. Colipase is produced by pancreatic acinar cells, stored in zymogen granules, and co‑secreted with PTL into the duodenum in response to cholecystokinin and secretin; under inflammatory conditions such as pancreatitis, exocrine secretion is disrupted and circulating levels of pancreatic enzymes increase (Am J Vet Res, 2022; J Lipid Res, 2002). URLs: https://doi.org/10.2460/ajvr.22.03.0048 (2022-08); https://doi.org/10.1194/jlr.r200012-jlr200 (2002-12) (lim2022lipasesitsnot pages 4-5, lowe2002thetriglyceridelipases pages 1-2)
- Pathways. CLPS functions in fat digestion and absorption and in the pancreatic secretion pathway, enabling efficient luminal lipolysis whose products enter mixed micelles for uptake (Ann Rev Nutr, 1997; Am J Vet Res, 2022). URLs: https://doi.org/10.1146/annurev.nutr.17.1.141 (1997-07); https://doi.org/10.2460/ajvr.22.03.0048 (2022-08) (lowe1997structureandfunction pages 3-6, lim2022lipasesitsnot pages 2-4)

Genomic location and gene regulation context
- Genomic locus. The human CLPS gene maps to chromosome 6p21.1–pter (Genomics, 1991). URL: https://doi.org/10.1016/0888-7543(91)90509-d (1991-05) (davis1991assignmentofthe pages 2-3)
- Regulatory context. Coordinated acinar secretion of PTL and CLPS is stimulated by gut hormones (CCK/secretin), matching their packaging in zymogen granules and co-release into the intestinal lumen (Am J Vet Res, 2022). URL: https://doi.org/10.2460/ajvr.22.03.0048 (2022-08) (lim2022lipasesitsnot pages 4-5)

Recent developments and latest research (2023–2024 prioritized)
- Plasma protein QTLs and T1D risk. A 2024 medRxiv preprint analyzing plasma pQTLs across 2,922 proteins and T1D GWAS loci reported colocalization of an RNLS locus with plasma levels of colipase (CLPS), highlighting exocrine pancreas contributions to T1D biology; Mendelian randomization supported causal roles for several proteins, while CLPS was noted in colocalization (preprint; not yet peer reviewed) (medRxiv, 2024-08-09). URL: https://doi.org/10.1101/2024.08.08.24311619 (2024-08) (elgamal2024circulatingpancreaticenzyme pages 1-4)
- Current physiology/clinical framing. Recent reviews continue to emphasize that colipase is required for optimal PTL activity at physiological bile salt concentrations and that PTL with colipase accounts for the majority of luminal triglyceride hydrolysis, integrating mechanistic and clinical perspectives across species (Am J Vet Res, 2022). URL: https://doi.org/10.2460/ajvr.22.03.0048 (2022-08) (lim2022lipasesitsnot pages 2-4)

Current applications and real-world implementations
- Digestive physiology and nutrition. Understanding CLPS is essential for interpreting fat digestion and for optimizing pancreatic enzyme replacement strategies where PTL must act at the lipid–water interface in the presence of bile salts; colipase is the physiological cofactor that restores activity in this context (J Lipid Res, 2002; Am J Vet Res, 2022). URLs: https://doi.org/10.1194/jlr.r200012-jlr200 (2002-12); https://doi.org/10.2460/ajvr.22.03.0048 (2022-08) (lowe2002thetriglyceridelipases pages 1-2, lim2022lipasesitsnot pages 2-4)
- Pancreatic disease biomarkers. In pancreatitis, exocrine secretion polarity is lost and pancreatic enzymes increase in circulation; while pancreatic lipase is the routine biomarker, colipase’s co-secretion and acinar origin contextualize its potential as a component of broader exocrine signatures (Am J Vet Res, 2022). URL: https://doi.org/10.2460/ajvr.22.03.0048 (2022-08) (lim2022lipasesitsnot pages 4-5)
- Emerging omics biomarker research. The 2024 pQTL/T1D colocalization for CLPS suggests potential biomarker development and motivates targeted validation of CLPS levels in autoimmunity risk stratification, pending peer review and replication (medRxiv, 2024-08-09). URL: https://doi.org/10.1101/2024.08.08.24311619 (2024-08) (elgamal2024circulatingpancreaticenzyme pages 1-4)

Expert opinions and authoritative perspectives
- Mechanistic consensus. Authoritative reviews agree that colipase is indispensable for optimal PTL function in vivo at physiological bile salt levels, primarily by anchoring PTL at micelles and stabilizing the open-lid conformation for interfacial catalysis (Ann Rev Nutr, 1997; J Lipid Res, 2002; Am J Vet Res, 2022). URLs: https://doi.org/10.1146/annurev.nutr.17.1.141 (1997-07); https://doi.org/10.1194/jlr.r200012-jlr200 (2002-12); https://doi.org/10.2460/ajvr.22.03.0048 (2022-08) (lowe1997structureandfunction pages 3-6, lowe2002thetriglyceridelipases pages 1-2, lim2022lipasesitsnot pages 2-4)
- Structural insights. Structural and mutational studies delineate the colipase three-finger fold and PTL C-terminal binding site, and identify a hydrophobic 5‑loop and colipase contact residues that are critical for forming the interfacial catalytic platform (Biochemistry, 1999; J Lipid Res, 2002). URLs: https://doi.org/10.1021/bi982601x (1999-04); https://doi.org/10.1194/jlr.r200012-jlr200 (2002-12) (bezzine1999humanpancreaticlipase pages 1-2, lowe2002thetriglyceridelipases pages 7-8)

Relevant statistics and data
- Quantitative contribution to dietary fat hydrolysis. PTL in complex with colipase is responsible for roughly 75% of dietary triglyceride hydrolysis in the intestinal lumen, underscoring CLPS’s physiological importance (Am J Vet Res, 2022). URL: https://doi.org/10.2460/ajvr.22.03.0048 (2022-08) (lim2022lipasesitsnot pages 4-5)
- Genetic/physiological evidence of requirement. In vivo models demonstrate that colipase deficiency leads to steatorrhea and undigested lipids on high-fat diets, indicating partial compensation by other lipases only under low-fat conditions (J Lipid Res, 2002). URL: https://doi.org/10.1194/jlr.r200012-jlr200 (2002-12) (lowe2002thetriglyceridelipases pages 2-3)

Verification of identity and avoidance of symbol ambiguity
- The gene symbol CLPS (HGNC:2085) refers to human pancreatic colipase, consistent with UniProt P04118 and all cited literature. No conflicting human gene usage for “CLPS” was identified in recent or foundational sources. The organism is Homo sapiens, and the protein belongs to the colipase family with the expected three-finger, disulfide-stabilized fold and procolipase processing (Ann Rev Nutr, 1997; Genomics, 1991; J Lipid Res, 2002). URLs: https://doi.org/10.1146/annurev.nutr.17.1.141 (1997-07); https://doi.org/10.1016/0888-7543(91)90509-d (1991-05); https://doi.org/10.1194/jlr.r200012-jlr200 (2002-12) (lowe1997structureandfunction pages 3-6, davis1991assignmentofthe pages 2-3, lowe2002thetriglyceridelipases pages 1-2)

Concise summary table
| Topic | Key Finding | Biological Context / Mechanism | Primary Sources (with year) | URL(s) |
|---|---|---|---|---|
| Identity / organism | CLPS encodes human pancreatic colipase, a small secreted cofactor (~10–12 kDa) for pancreatic triglyceride lipase (PNLIP). | Secreted by pancreatic acinar cells; three-finger, disulfide-stabilized fold that binds lipase C-terminal domain to enable activity at lipid interfaces. | Lowe 1997 (lowe1997structureandfunction pages 3-6), Lim 2022 (lim2022lipasesitsnot pages 2-4) | https://doi.org/10.1146/annurev.nutr.17.1.141, https://doi.org/10.2460/ajvr.22.03.0048 |
| Biochemical function (bile salts & interfacial activation) | Colipase restores activity to bile-salt-inhibited pancreatic lipase and enables interfacial activation of triglyceride hydrolysis. | Binds lipase and anchors it to bile-salt–lined micelles/oil–water interfaces; stabilizes the lid-open conformation to expose the catalytic site. | Bezzine 1999 (bezzine1999humanpancreaticlipase pages 1-2), Lowe 2002 (lowe2002thetriglyceridelipases pages 1-2) | https://doi.org/10.1021/bi982601x, https://doi.org/10.1194/jlr.r200012-jlr200 |
| Binding surfaces (structural contacts) | Colipase adopts a three-finger topology; key colipase residues (e.g., Glu45, Glu64, Arg65, Asn89) contact PTL residues (Asn366, Gln369, Lys400); PTL 5-loop (residues ~405–414) forms a hydrophobic interface. | Colipase + open lid + PTL surfaces create a continuous hydrophobic plateau for interfacial binding and substrate engagement. | Lowe 2002 (lowe2002thetriglyceridelipases pages 7-8), Bezzine 1999 (bezzine1999humanpancreaticlipase pages 1-2) | https://doi.org/10.1194/jlr.r200012-jlr200, https://doi.org/10.1021/bi982601x |
| Procolipase processing & enterostatin | CLPS is synthesized as procolipase and activated by trypsin cleavage that releases an N-terminal pentapeptide (enterostatin); enterostatin has been shown in animal studies to reduce fat intake. | Activation occurs in the duodenum; enterostatin is present in lumen/circulation and may act as a satiety/signaling peptide (animal evidence). | Lowe 1997 (lowe1997structureandfunction pages 3-6) | https://doi.org/10.1146/annurev.nutr.17.1.141 |
| Secretion & localization | Synthesized in pancreatic acinar cells, packaged in zymogen granules, co-secreted with pancreatic lipase into the intestinal lumen in response to CCK/secretin; low basal plasma levels increase with pancreatic inflammation. | Exocrine secretion into duodenum where colipase interacts with bile salts/lipase; misrouting (pancreatitis) elevates circulating enzyme levels. | Lim 2022 (lim2022lipasesitsnot pages 2-4), Lowe 2002 (lowe2002thetriglyceridelipases pages 1-2) | https://doi.org/10.2460/ajvr.22.03.0048, https://doi.org/10.1194/jlr.r200012-jlr200 |
| Pathway membership | Component of fat digestion & absorption and pancreatic secretion pathways; facilitates hydrolysis of dietary triacylglycerols to di- and monoacylglycerols and free fatty acids for micellar uptake. | Works with pancreatic lipase and bile salts to generate absorbable lipolytic products incorporated into mixed micelles for enterocyte uptake and chylomicron assembly. | Lowe 1997 (lowe1997structureandfunction pages 3-6), Lim 2022 (lim2022lipasesitsnot pages 2-4) | https://doi.org/10.1146/annurev.nutr.17.1.141, https://doi.org/10.2460/ajvr.22.03.0048 |
| Genomic locus | Human CLPS maps to chromosome 6p21.1–pter. | Genomic mapping places CLPS on chromosome 6, consistent with gene annotation resources. | Davis 1991 (davis1991assignmentofthe pages 2-3) | https://doi.org/10.1016/0888-7543(91)90509-d |
| Disease / clinical links | Colipase deficiency (mouse) → steatorrhea on high-fat diets; pancreatitis disrupts exocrine secretion increasing circulating pancreatic enzymes; 2024 pQTL preprint reports colocalization of a plasma protein QTL with CLPS at an RNLS-associated locus (implicating exocrine pancreas in T1D genetics). | Clinical relevance in fat malabsorption/exocrine pancreatic dysfunction; emerging omics evidence links plasma CLPS levels to disease-associated loci (potential biomarker role). | Lowe 2002 (lowe2002thetriglyceridelipases pages 2-3), Elgamal 2024 (elgamal2024circulatingpancreaticenzyme pages 1-4) | https://doi.org/10.1194/jlr.r200012-jlr200, https://doi.org/10.1101/2024.08.08.24311619 |
| Quantitative contribution to TG hydrolysis | Pancreatic lipase acting with colipase accounts for the majority (~75%) of dietary triglyceride hydrolysis in the intestinal lumen. | Colipase is essential for optimal PTL activity at physiological bile-salt concentrations; other lipases can partially compensate under low-fat diets. | Lim 2022 (lim2022lipasesitsnot pages 2-4), Lowe 2002 (lowe2002thetriglyceridelipases pages 1-2) | https://doi.org/10.2460/ajvr.22.03.0048, https://doi.org/10.1194/jlr.r200012-jlr200 |

Table: Concise, citable summary of key facts about human CLPS (colipase), including function, structure, processing, localization, genomic locus, pathway membership, clinical links, and primary literature sources to support a research report.

Gaps and open questions
- Human enterostatin physiology remains less certain than rodent data; rigorous trials are needed to establish its role, receptor(s), and pharmacology in humans (Ann Rev Nutr, 1997). URL: https://doi.org/10.1146/annurev.nutr.17.1.141 (1997-07) (lowe1997structureandfunction pages 3-6)
- The 2024 CLPS pQTL–T1D colocalization is promising but requires peer-reviewed confirmation, functional dissection (tissue of action, regulation), and prospective biomarker validation (medRxiv, 2024-08-09). URL: https://doi.org/10.1101/2024.08.08.24311619 (2024-08) (elgamal2024circulatingpancreaticenzyme pages 1-4)

References (URLs and dates embedded above)
- Lim SY, Steiner JM, Cridge H. Lipases: it’s not just pancreatic lipase! Am J Vet Res. 2022-08. https://doi.org/10.2460/ajvr.22.03.0048 (lim2022lipasesitsnot pages 2-4, lim2022lipasesitsnot pages 4-5)
- Lowe ME. The triglyceride lipases of the pancreas. J Lipid Res. 2002-12. https://doi.org/10.1194/jlr.r200012-jlr200 (lowe2002thetriglyceridelipases pages 1-2, lowe2002thetriglyceridelipases pages 2-3, lowe2002thetriglyceridelipases pages 7-8)
- Lowe ME. Structure and function of pancreatic lipase and colipase. Annu Rev Nutr. 1997-07. https://doi.org/10.1146/annurev.nutr.17.1.141 (lowe1997structureandfunction pages 3-6, lowe1997structureandfunction pages 16-17)
- Bezzine S et al. Human pancreatic lipase: colipase dependence and interfacial binding of lid domain mutants. Biochemistry. 1999-04. https://doi.org/10.1021/bi982601x (bezzine1999humanpancreaticlipase pages 1-2)
- Davis RC et al. Assignment of the human pancreatic colipase gene to chromosome 6p21.1 to pter. Genomics. 1991-05. https://doi.org/10.1016/0888-7543(91)90509-d (davis1991assignmentofthe pages 2-3)
- Elgamal RM et al. Circulating pancreatic enzyme levels are a causal biomarker of type 1 diabetes. medRxiv. 2024-08-09. https://doi.org/10.1101/2024.08.08.24311619 (elgamal2024circulatingpancreaticenzyme pages 1-4)

References

1. (lim2022lipasesitsnot pages 2-4): Sue Yee Lim, Jörg M. Steiner, and Harry Cridge. Lipases: it's not just pancreatic lipase! American Journal of Veterinary Research, Aug 2022. URL: https://doi.org/10.2460/ajvr.22.03.0048, doi:10.2460/ajvr.22.03.0048. This article has 61 citations and is from a domain leading peer-reviewed journal.

2. (lim2022lipasesitsnot pages 4-5): Sue Yee Lim, Jörg M. Steiner, and Harry Cridge. Lipases: it's not just pancreatic lipase! American Journal of Veterinary Research, Aug 2022. URL: https://doi.org/10.2460/ajvr.22.03.0048, doi:10.2460/ajvr.22.03.0048. This article has 61 citations and is from a domain leading peer-reviewed journal.

3. (lowe2002thetriglyceridelipases pages 1-2): Mark E. Lowe. The triglyceride lipases of the pancreas published, jlr papers in press, october 1, 2002. doi 10.1194/jlr.r200012-jlr200. Journal of Lipid Research, 43:2007-2016, Dec 2002. URL: https://doi.org/10.1194/jlr.r200012-jlr200, doi:10.1194/jlr.r200012-jlr200. This article has 431 citations and is from a peer-reviewed journal.

4. (lowe2002thetriglyceridelipases pages 2-3): Mark E. Lowe. The triglyceride lipases of the pancreas published, jlr papers in press, october 1, 2002. doi 10.1194/jlr.r200012-jlr200. Journal of Lipid Research, 43:2007-2016, Dec 2002. URL: https://doi.org/10.1194/jlr.r200012-jlr200, doi:10.1194/jlr.r200012-jlr200. This article has 431 citations and is from a peer-reviewed journal.

5. (lowe2002thetriglyceridelipases pages 7-8): Mark E. Lowe. The triglyceride lipases of the pancreas published, jlr papers in press, october 1, 2002. doi 10.1194/jlr.r200012-jlr200. Journal of Lipid Research, 43:2007-2016, Dec 2002. URL: https://doi.org/10.1194/jlr.r200012-jlr200, doi:10.1194/jlr.r200012-jlr200. This article has 431 citations and is from a peer-reviewed journal.

6. (davis1991assignmentofthe pages 2-3): Richard C. Davis, Yurong Xia, T. Mohandas, Michael C. Schotz, and Aldons J. Lusis. Assignment of the human pancreatic colipase gene to chromosome 6p21.1 to pter. Genomics, 10:262-265, May 1991. URL: https://doi.org/10.1016/0888-7543(91)90509-d, doi:10.1016/0888-7543(91)90509-d. This article has 21 citations and is from a peer-reviewed journal.

7. (elgamal2024circulatingpancreaticenzyme pages 1-4): Ruth M Elgamal, Rebecca L. Melton, Joshua Chiou, Carolyn W McGrail, and Kyle J Gaulton. Circulating pancreatic enzyme levels are a causal biomarker of type 1 diabetes. medRxiv, Aug 2024. URL: https://doi.org/10.1101/2024.08.08.24311619, doi:10.1101/2024.08.08.24311619. This article has 2 citations.

8. (lowe1997structureandfunction pages 3-6): Mark E. Lowe. Structure and function of pancreatic lipase and colipase. Annual review of nutrition, 17:141-58, Jul 1997. URL: https://doi.org/10.1146/annurev.nutr.17.1.141, doi:10.1146/annurev.nutr.17.1.141. This article has 191 citations and is from a highest quality peer-reviewed journal.

9. (bezzine1999humanpancreaticlipase pages 1-2): Sofiane Bezzine, Francine Ferrato, Margarita G. Ivanova, Véronique Lopez, Robert Verger, and Frédéric Carrière. Human pancreatic lipase: colipase dependence and interfacial binding of lid domain mutants. Biochemistry, 38 17:5499-510, Apr 1999. URL: https://doi.org/10.1021/bi982601x, doi:10.1021/bi982601x. This article has 87 citations and is from a peer-reviewed journal.

10. (lowe1997structureandfunction pages 16-17): Mark E. Lowe. Structure and function of pancreatic lipase and colipase. Annual review of nutrition, 17:141-58, Jul 1997. URL: https://doi.org/10.1146/annurev.nutr.17.1.141, doi:10.1146/annurev.nutr.17.1.141. This article has 191 citations and is from a highest quality peer-reviewed journal.

Citations

1. lowe1997structureandfunction pages 3-6
2. davis1991assignmentofthe pages 2-3
3. lim2022lipasesitsnot pages 4-5
4. elgamal2024circulatingpancreaticenzyme pages 1-4
5. lim2022lipasesitsnot pages 2-4
6. lowe2002thetriglyceridelipases pages 2-3
7. bezzine1999humanpancreaticlipase pages 1-2
8. lowe2002thetriglyceridelipases pages 1-2
9. lowe2002thetriglyceridelipases pages 7-8
10. lowe1997structureandfunction pages 16-17
11. https://doi.org/10.1146/annurev.nutr.17.1.141
12. https://doi.org/10.1194/jlr.r200012-jlr200
13. https://doi.org/10.1021/bi982601x
14. https://doi.org/10.2460/ajvr.22.03.0048
15. https://doi.org/10.1016/0888-7543(91
16. https://doi.org/10.1101/2024.08.08.24311619
17. https://doi.org/10.1146/annurev.nutr.17.1.141,
18. https://doi.org/10.1021/bi982601x,
19. https://doi.org/10.1194/jlr.r200012-jlr200,
20. https://doi.org/10.2460/ajvr.22.03.0048,
21. https://doi.org/10.1101/2024.08.08.24311619,

CLPS (Colipase) Gene in Humans – Functional Annotation and Research Overview

Overview and Gene Product Identity

The human CLPS gene encodes colipase, a small protein cofactor essential for pancreatic triglyceride lipase activity and dietary fat digestion (gosset.ai). Colipase is produced as a 112–amino acid preproprotein (UniProt P04118) that includes a signal peptide and an activation segment (pmc.ncbi.nlm.nih.gov). It is exclusively expressed in the exocrine pancreas – particularly in acinar cells – and secreted into pancreatic juice as procolipase (www.ncbi.nlm.nih.gov). During digestion, procolipase is activated by trypsin cleavage in the duodenum, yielding active colipase and releasing a small N-terminal pentapeptide called enterostatin (gosset.ai) (pmc.ncbi.nlm.nih.gov). The CLPS gene is located on chromosome 6p21.31 (pmc.ncbi.nlm.nih.gov) and exhibits highly tissue-specific expression (e.g. ~17,700 RPKM in pancreas, with essentially no expression in other tissues) (www.ncbi.nlm.nih.gov). This extreme enrichment reflects colipase’s dedicated role in pancreatic exocrine function.

Molecular Function and Mechanism of Colipase

Colipase itself has no enzymatic activity; instead, it serves as a critical cofactor that enables pancreatic triglyceride lipase (PTL) to function optimally in the intestinal lumen (gosset.ai). One colipase binds stoichiometrically to one lipase molecule, targeting the C-terminal, non-catalytic domain of PTL (www.genecards.org). This interaction stabilizes lipase in an open, active conformation and expands its hydrophobic surface, greatly enhancing the enzyme’s ability to bind lipid substrates (www.genecards.org). Colipase also has a high affinity for lipid–water interfaces: it can bind to emulsified dietary fat droplets (micelles) and simultaneously tether the lipase enzyme there (gosset.ai). In essence, colipase anchors and stabilizes pancreatic lipase at the lipid interface even in the presence of bile salts, which would otherwise displace or inhibit the enzyme (gosset.ai) (www.ncbi.nlm.nih.gov). By counteracting bile salt-mediated inhibition, colipase permits pancreatic lipase to efficiently hydrolyze triglycerides into fatty acids and 2-monoglycerides – the absorbable forms of fat (gosset.ai) (www.ncbi.nlm.nih.gov).

Key mechanism: In the intestinal lumen, dietary fats are first emulsified by bile. Pancreatic lipase alone has reduced activity on emulsified triglycerides when bile acids are present, because bile acids can strip lipase off the fat droplet surface. Colipase is indispensable for lipase function under these conditions (pubmed.ncbi.nlm.nih.gov). It acts as a bridging molecule, one side binding tightly to lipase and the other embedding into the lipid droplet. Classic experiments demonstrated that beyond a certain interfacial tension (as occurs in bile-rich micelles), lipase cannot adsorb to fat droplets without colipase (pubmed.ncbi.nlm.nih.gov). Colipase thus restores or “reactivates” lipase activity in the intestinal environment (pmc.ncbi.nlm.nih.gov). In vivo, pancreatic triglyceride lipase is essentially ineffective without its colipase partner (pubmed.ncbi.nlm.nih.gov) – together, they form a 1:1 lipase–colipase complex that is the active unit for fat breakdown. Structural studies confirm the strength and specificity of this complex: colipase–lipase binding is stabilized by multiple hydrogen bonds and extensive surface contacts (~80 van der Waals interactions) at the interface of colipase and the lipase’s C-terminal domain (pmc.ncbi.nlm.nih.gov). Through these interactions, colipase prevents lipase denaturation at the water–lipid interface and maintains the enzyme in the correct orientation for catalysis (pubmed.ncbi.nlm.nih.gov). The net effect is a dramatic increase in the efficiency of triglyceride hydrolysis in the small intestine.

Biological Role in Digestion and Physiology

Dietary fat digestion: Colipase plays a central role in lipid catabolism as part of the pancreatic enzyme system. It is required for the normal digestion and absorption of long-chain dietary triglycerides in the small intestine (www.ncbi.nlm.nih.gov). The lipase–colipase enzyme system acts in the lumen of the duodenum and jejunum to generate fatty acids and monoglycerides, which are then absorbed by enterocytes. In the absence of functional colipase, pancreatic lipase cannot properly act on emulsified fats, leading to severe fat malabsorption. This is evidenced clinically and in animal models – colipase deficiency or inactivity causes steatorrhea (excess fat in stool) and symptoms of exocrine pancreatic insufficiency (gosset.ai). For example, patients or experimental animals lacking colipase activity exhibit oily diarrhea and weight loss due to undigested fat, underscoring the cofactor’s essential role in nutrient absorption (gosset.ai). Consistently, pancreatic enzyme replacement therapies for pancreatic insufficiency (e.g. pancrelipase supplements) rely on sources that provide not only lipase but also colipase activity to ensure efficacy (pmc.ncbi.nlm.nih.gov) (gosset.ai).

Pathways and interactions: Colipase operates at the intersection of digestive pathways: it is secreted alongside pancreatic lipase (encoded by the PNLIP gene) into the duodenum as part of the pancreatic juice. There, it interacts with other key molecules of fat digestion – notably bile salts (taurocholate, etc.) and the lipid substrate itself. Colipase doesn’t participate in classic signaling cascades, but its action is integral to the biochemical pathway of triglyceride breakdown. In a broader nutritional context, colipase function ensures that dietary fats (which are hydrophobic) can be broken down in an aqueous environment and absorbed. Additionally, colipase may assist other fat-degrading enzymes: while pancreatic triglyceride lipase is its primary partner, colipase can also bind and support pancreatic lipase-related proteins on certain substrates (pmc.ncbi.nlm.nih.gov), though pancreatic PTL is the main enzyme requiring colipase (pmc.ncbi.nlm.nih.gov). In neonates (who have low pancreatic lipase expression immediately after birth), colipase is present and might contribute to fat digestion via alternate lipases (e.g. human milk bile-salt stimulated lipase or gastric lipase); this suggests a possible supportive role for colipase in early life nutrition (pmc.ncbi.nlm.nih.gov). Notably, colipase itself is not a signaling molecule, but interestingly, its precursor peptide has been implicated in metabolic signaling (see below). Overall, colipase’s activity is tightly linked to the digestive process and is a critical factor in the intestinal phase of fat metabolism.

Activation, Regulation, and Enterostatin

Newly synthesized colipase is an inactive zymogen (procolipase) that undergoes proteolytic activation. In the pancreatic acinar cell, procolipase (approximately 10 kDa) is packaged into zymogen granules and co-released with digestive enzymes. Trypsin (another pancreatic enzyme) cleaves procolipase in the duodenum, removing a 5-amino-acid activation peptide from the N-terminus (pmc.ncbi.nlm.nih.gov). This cleavage converts the inactive precursor into active colipase capable of binding lipase. The small liberated peptide is enterostatin (sequence Val-Pro-Asp-Pro-Arg in humans) (pmc.ncbi.nlm.nih.gov). Intriguingly, enterostatin is biologically active on its own: it has been shown in rodents and other animals to function as a satiety or signaling peptide related to fat intake. Erlanson-Albertsson and colleagues first proposed enterostatin as a feedback signal for dietary fat regulation (pmc.ncbi.nlm.nih.gov). In rats, peripheral or central administration of enterostatin selectively reduces fat consumption (i.e. the animals eat less fat) (pmc.ncbi.nlm.nih.gov). For example, Okada et al. (1991) demonstrated that enterostatin treatment led to significantly decreased fat intake in rats (pmc.ncbi.nlm.nih.gov). The working model is that when the pancreas secretes more procolipase (for fat digestion), more enterostatin is generated in the gut, which then signals the brain to curb appetite for fatty foods (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This provides a negative feedback loop to prevent overconsumption of fat. Consistent with this idea, high-fat feeding increases CLPS (procolipase) expression in the pancreas (pmc.ncbi.nlm.nih.gov), presumably producing more enterostatin to limit further fat intake. However, this regulatory mechanism is complex and species-dependent. In humans, the physiological role of enterostatin remains less clear – some studies explored associations of CLPS gene variants with obesity and feeding behavior. For instance, Wermter et al. (2010) found no strong genetic association between common CLPS polymorphisms and early-onset obesity in humans (pmc.ncbi.nlm.nih.gov), suggesting that if enterostatin influences appetite, its impact might be subtle or compensable. Nonetheless, the procolipase–enterostatin system illustrates how closely pancreatic digestive function is linked to nutritional feedback signals.

Beyond dietary regulation, the CLPS gene itself appears to be predominantly regulated at the tissue-specific level. It is expressed almost exclusively in pancreatic acinar cells (www.ncbi.nlm.nih.gov), under the control of pancreatic transcription factors and secretagogue signals (e.g. cholecystokinin stimulates its secretion as part of the pancreatic enzyme release). RefSeq annotations note that CLPS has a few transcript variants encoding the same or similar colipase protein (www.ncbi.nlm.nih.gov), but no major isoform with a different function has been reported. The high specificity of expression implies that upstream regulatory elements ensure colipase is produced only where needed (pancreas) and in coordination with lipase and other digestive enzymes.

Structural Features of Colipase

Colipase is a small, cysteine-rich protein composed of about 100 amino acids (excluding the signal and activation peptides). It has a distinctive flattened, globular structure roughly 25×30×35 Å in size (www.sigmaaldrich.com). Uniquely, colipase lacks extensive regular secondary structure – it does not fold into significant alpha-helices or beta-sheets. Instead, its conformation is stabilized by an extended network of five disulfide bonds that span the protein (pmc.ncbi.nlm.nih.gov). The human colipase contains 10 cysteine residues that form 5 intramolecular disulfide bridges (pmc.ncbi.nlm.nih.gov). These disulfides “staple” the protein into a stable shape consisting of several loop regions. In fact, colipase is often described as having four or five finger-like loops protruding from a relatively flat core (pmc.ncbi.nlm.nih.gov). This disulfide-reinforced loop structure is critical for function: it endows colipase with high stability against proteases and bile in the harsh intestinal environment, and it creates distinct interaction surfaces for lipase and lipids (pmc.ncbi.nlm.nih.gov).

One face of the colipase molecule is hydrophilic and interacts with pancreatic lipase, while the opposite face is hydrophobic, formed by the tips of the loops, and inserts into the lipid interface (pmc.ncbi.nlm.nih.gov). This bipartite surface distribution allows colipase to act as a bridge between water-soluble enzymes and hydrophobic fat droplets. Crystallographic studies of the porcine colipase–lipase complex (van Tilbeurgh et al., 1993; Egloff et al., 1995) provided detailed insight: the colipase–lipase interface involves numerous contacts (including ~8 hydrogen bonds) that ensure tight binding (pmc.ncbi.nlm.nih.gov). Meanwhile, the tip of colipase’s loops penetrates into the lipid layer, anchoring the complex at the triglyceride–water boundary. Site-directed mutagenesis experiments have pinpointed specific amino acids on colipase that mediate these interactions. For example, Tyr^55 on human colipase, located on one of the surface loops, is critical for adsorption to bile salt micelles (pmc.ncbi.nlm.nih.gov). A Y55A colipase mutant showed greatly reduced ability to restore lipase activity in the presence of bile, underscoring the importance of this hydrophobic loop residue in binding the lipid interface (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). Other loop residues (e.g. Leu^34/Leu^36 on loop 2 and Ile^75/Ile^79 on loop 4) have also been shown to contribute to the lipid-binding surface of colipase (pmc.ncbi.nlm.nih.gov). In contrast, mutations like Phe^84 located in the protein core mainly affect folding stability rather than direct lipid binding (pmc.ncbi.nlm.nih.gov). These findings from Lowe and colleagues (2013) provide a refined understanding of how colipase’s structure dictates its function at a molecular level.

Functional Implications and Current Research

Given its vital role in fat digestion, colipase has been studied in contexts of nutrition, disease, and even evolution. In terms of human health, colipase insufficiency is one contributing factor in malabsorptive disorders. In chronic pancreatitis or cystic fibrosis (where exocrine output is reduced), the lack of pancreatic colipase – alongside lipase – leads to steatorrhea that must be managed with pancreatic enzyme (and cofactor) replacement (pubmed.ncbi.nlm.nih.gov). Rare congenital cases of combined lipase-colipase deficiency have been reported, presenting in early childhood with failure to thrive due to fat malabsorption (pubmed.ncbi.nlm.nih.gov). Such cases highlight colipase’s non-redundant function: other lipases cannot compensate unless colipase is present to facilitate their action. Indeed, colipase is considered essential for normal fat absorption, and there is no known alternate human protein that can substitute for its cofactor activity (pubmed.ncbi.nlm.nih.gov).

At the same time, research has explored whether variations in the CLPS gene or colipase levels could influence metabolic outcomes like obesity and diabetes. While common variants in CLPS do not appear to strongly affect obesity risk (pmc.ncbi.nlm.nih.gov), a specific missense polymorphism has drawn attention. This variant is an arginine-to-cysteine substitution at position 92 (Arg92Cys) in colipase. Arg^92 lies in one of the colipase loops, and introducing an extra cysteine at this position disturbs the protein’s disulfide bond pattern. Studies by D’Silva, Lowe, and colleagues (published 2007–2013) showed that the Arg92Cys variant produces a colipase protein with impaired stability and function. The mutant colipase can still bind lipase and support the breakdown of short-chain triglycerides normally, but it retains only ~50% of wild-type activity when hydrolyzing long-chain triglycerides (pmc.ncbi.nlm.nih.gov). Functionally, the Cys92-colipase has trouble anchoring lipase to larger lipid emulsions, especially after exposure to conditions mimicking the gut. Notably, Cys92-colipase lost its activity upon storage, suggesting a propensity to misfold or aggregate over time (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov). This misfolding is likely due to the unpaired cysteine forming aberrant disulfide links. Population-genetic analyses further indicated that Arg92Cys in CLPS might be linked to metabolic traits – researchers found this variant at higher frequency in certain groups and proposed it may contribute to increased risk of type 2 diabetes (pmc.ncbi.nlm.nih.gov). The hypothesis is that a chronically less effective colipase could alter fat digestion efficiency or gut signaling in a way that influences metabolic homeostasis (pmc.ncbi.nlm.nih.gov). While more studies are needed to confirm such links, the Arg92Cys case exemplifies how structure–function relationships in colipase are clinically significant. It also underscores that colipase’s integrity (correct cysteine pairing and folding) is crucial for its cofactor activity.

On the translational front, there are currently no drugs targeting colipase directly – and none likely needed, since colipase is not an enzyme but a facilitator protein (gosset.ai). However, understanding colipase has practical implications. Nutritional interventions for patients with pancreatic insufficiency rely on porcine pancreatic extracts containing both lipase and colipase activity to recapitulate the natural digestive process (pmc.ncbi.nlm.nih.gov). Moreover, any future techniques to engineer improved enzyme replacement (for example, genetically engineered lipases) must ensure colipase compatibility. In biotechnology, colipase is sometimes added to in vitro fat digestion assays or industrial processes to enhance lipase performance (pubmed.ncbi.nlm.nih.gov). There is also interest in whether modulating the enterostatin pathway could affect dietary habits or weight loss, though clinical applications there remain speculative (pmc.ncbi.nlm.nih.gov).

Expert Perspectives and Conclusions

Colipase is a quintessential example of a small cofactor protein that enables an enzyme to function under physiological conditions that would otherwise be prohibitive. As early as the 1970s, investigators recognized that pancreatic lipase alone was ineffective in the intestinal lumen and that a heat-stable cofactor was required for triglyceride digestion (pmc.ncbi.nlm.nih.gov). Decades of research have since firmly established colipase’s role in anchoring lipase at the lipid–water interface and preventing bile salt inhibition. Mark Lowe, a leading expert on pancreatic lipases, summarized that “in vivo, lipase action cannot take place without colipase”, emphasizing colipase’s indispensable role (pubmed.ncbi.nlm.nih.gov). Structurally, colipase represents an elegant adaptation: its disulfide-stabilized, amphipathic design allows it to straddle two worlds – water and oil – to bring together enzyme and substrate. Functionally, it acts as a molecular tether and activation platform for pancreatic lipase.

From a biological process standpoint, colipase is tightly integrated into the fat digestion pathway. Its activity exemplifies the cooperative nature of digestion, where multiple components (bile acids, lipase, co-lipase) work in concert to achieve efficient nutrient breakdown. The physiological importance of colipase is further highlighted by the body’s regulatory investment in it – from selective expression in the pancreas to potential feedback signals (enterostatin) that link digestive capacity with feeding behavior (pmc.ncbi.nlm.nih.gov) (pmc.ncbi.nlm.nih.gov).

In summary, CLPS (colipase) encodes a crucial cofactor that enables dietary triglyceride assimilation in humans. The colipase protein’s specific binding to pancreatic lipase and lipid interfaces overcomes the barriers presented by an aqueous, bile-rich intestinal environment (www.ncbi.nlm.nih.gov). By stabilizing and localizing lipase at the fat droplet surface, colipase ensures that fat is efficiently hydrolyzed and made available for absorption (www.ncbi.nlm.nih.gov) (gosset.ai). Its role is precise and fundamental – rather than broadly pleiotropic – and it illustrates how a small protein can have a large impact on metabolic physiology. Ongoing research, from detailed mutation analyses to clinical genetic studies, continues to refine our understanding of colipase’s function and its implications in health and disease. The current understanding portrays colipase as an essential facilitator of lipid digestion, with a well-defined action mechanism and a clear importance in nutrition and pancreatic function.

References: (Key sources highlighting colipase function, structure, and physiology have been cited in-line, with URLs and publication details provided. These include foundational biochemical studies, structural analyses from the 1990s, and research up through the 2010s examining genetic variants and regulatory aspects of CLPS.)

Citations

1. AnnotationURLCitation(end_index=377, start_index=269, title='Gosset', type='url_citation', url='https://gosset.ai/targets/colipase/#:~:text=Colipase%20,from%20the%20pancreas%20as%20inactive')
2. AnnotationURLCitation(end_index=660, start_index=508, title='Procolipase Gene: No Association with Early-Onset Obesity or Fat Intake - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6444705/#:~:text=The%20human%20procolipase%20gene%20,and%20fat%20intake%20in%20German')
3. AnnotationURLCitation(end_index=936, start_index=800, title='CLPS colipase [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/1208#:~:text=catalytic%20domain%20of%20lipase%2C%20thereby,6%29%20See%20more')
4. AnnotationURLCitation(end_index=1263, start_index=1113, title='Gosset', type='url_citation', url='https://gosset.ai/targets/colipase/#:~:text=indispensable%20structural%20role%20in%20enabling,impaired%20fat%20absorption%20but%20there')
5. AnnotationURLCitation(end_index=1454, start_index=1264, title='Procolipase Gene: No Association with Early-Onset Obesity or Fat Intake - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6444705/#:~:text=match%20at%20L393%20%2A%201.Erlanson,4887.1992.tb02473.x.%20%5BDOI%5D%20%5BPubMed%5D%20%5BGoogle%20Scholar')
6. AnnotationURLCitation(end_index=1655, start_index=1503, title='Procolipase Gene: No Association with Early-Onset Obesity or Fat Intake - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6444705/#:~:text=The%20human%20procolipase%20gene%20,and%20fat%20intake%20in%20German')
7. AnnotationURLCitation(end_index=1920, start_index=1784, title='CLPS colipase [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/1208#:~:text=allows%20lipase%20to%20anchor%20noncovalently,6%29%20See%20more')
8. AnnotationURLCitation(end_index=2364, start_index=2256, title='Gosset', type='url_citation', url='https://gosset.ai/targets/colipase/#:~:text=Colipase%20,from%20the%20pancreas%20as%20inactive')
9. AnnotationURLCitation(end_index=2617, start_index=2484, title='CLPS Gene - GeneCards | COL Protein | COL Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=CLPS#:~:text=The%20protein%20encoded%20by%20this,See%20more')
10. AnnotationURLCitation(end_index=2924, start_index=2791, title='CLPS Gene - GeneCards | COL Protein | COL Antibody', type='url_citation', url='https://www.genecards.org/cgi-bin/carddisp.pl?gene=CLPS#:~:text=The%20protein%20encoded%20by%20this,See%20more')
11. AnnotationURLCitation(end_index=3204, start_index=3096, title='Gosset', type='url_citation', url='https://gosset.ai/targets/colipase/#:~:text=Colipase%20,from%20the%20pancreas%20as%20inactive')
12. AnnotationURLCitation(end_index=3492, start_index=3384, title='Gosset', type='url_citation', url='https://gosset.ai/targets/colipase/#:~:text=Colipase%20,from%20the%20pancreas%20as%20inactive')
13. AnnotationURLCitation(end_index=3616, start_index=3493, title='CLPS colipase [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/1208#:~:text=catalytic%20domain%20of%20lipase%2C%20thereby,This')
14. AnnotationURLCitation(end_index=3951, start_index=3808, title='Gosset', type='url_citation', url='https://gosset.ai/targets/colipase/#:~:text=anchoring%20and%20stabilizing%20the%20enzyme,enzymatic%20activity%20but%20plays%20an')
15. AnnotationURLCitation(end_index=4109, start_index=3952, title='CLPS colipase [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/1208#:~:text=catalytic%20domain%20of%20lipase%2C%20thereby,provided%20by%20RefSeq%2C%20Nov%202011')
16. AnnotationURLCitation(end_index=4591, start_index=4440, title='[Recent findings on pancreatic lipase and colipase] - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/6373427/#:~:text=that%20of%20other%20esterases,hydrophobic%20region%20and%20by%20ionizable')
17. AnnotationURLCitation(end_index=5027, start_index=4876, title='[Recent findings on pancreatic lipase and colipase] - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/6373427/#:~:text=that%20of%20other%20esterases,hydrophobic%20region%20and%20by%20ionizable')
18. AnnotationURLCitation(end_index=5274, start_index=5117, title='Procolipase Gene: No Association with Early-Onset Obesity or Fat Intake - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6444705/#:~:text=mature%20protein%20colipase%20,efficient%20digestion%20of%20dietary%20fat')
19. AnnotationURLCitation(end_index=5523, start_index=5372, title='[Recent findings on pancreatic lipase and colipase] - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/6373427/#:~:text=that%20of%20other%20esterases,hydrophobic%20region%20and%20by%20ionizable')
20. AnnotationURLCitation(end_index=6011, start_index=5889, title='Crystallographic study of the structure of colipase and of the interaction with pancreatic lipase - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2142970/#:~:text=lacks%20well,Upon%20opening%20of%20the')
21. AnnotationURLCitation(end_index=6325, start_index=6174, title='[Recent findings on pancreatic lipase and colipase] - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/6373427/#:~:text=that%20of%20other%20esterases,hydrophobic%20region%20and%20by%20ionizable')
22. AnnotationURLCitation(end_index=6875, start_index=6718, title='CLPS colipase [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/1208#:~:text=catalytic%20domain%20of%20lipase%2C%20thereby,provided%20by%20RefSeq%2C%20Nov%202011')
23. AnnotationURLCitation(end_index=7439, start_index=7358, title='Gosset', type='url_citation', url='https://gosset.ai/targets/colipase/#:~:text=Disease%20Associations')
24. AnnotationURLCitation(end_index=7721, start_index=7640, title='Gosset', type='url_citation', url='https://gosset.ai/targets/colipase/#:~:text=Disease%20Associations')
25. AnnotationURLCitation(end_index=8106, start_index=7929, title='Delayed release pancrelipase for treatment of pancreatic exocrine insufficiency associated with chronic pancreatitis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2710383/#:~:text=insufficiency%20associated%20with%20chronic%20pancreatitis,be%20degraded%20in%20the%20stomach')
26. AnnotationURLCitation(end_index=8188, start_index=8107, title='Gosset', type='url_citation', url='https://gosset.ai/targets/colipase/#:~:text=Disease%20Associations')
27. AnnotationURLCitation(end_index=9191, start_index=9065, title='Pancreatic lipase-related protein 2 digests fats in human milk and formula in concert with gastric lipase and carboxyl ester lipase - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3737390/#:~:text=Pancreatic%20lipase,PAGE.%20Each%20protein')
28. AnnotationURLCitation(end_index=9410, start_index=9253, title='Procolipase Gene: No Association with Early-Onset Obesity or Fat Intake - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6444705/#:~:text=mature%20protein%20colipase%20,efficient%20digestion%20of%20dietary%20fat')
29. AnnotationURLCitation(end_index=9851, start_index=9716, title='Procolipase Gene: No Association with Early-Onset Obesity or Fat Intake - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6444705/#:~:text=wild,of%20enterostatin%2C%20either%20centrally%20or')
30. AnnotationURLCitation(end_index=10780, start_index=10590, title='Procolipase Gene: No Association with Early-Onset Obesity or Fat Intake - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6444705/#:~:text=match%20at%20L393%20%2A%201.Erlanson,4887.1992.tb02473.x.%20%5BDOI%5D%20%5BPubMed%5D%20%5BGoogle%20Scholar')
31. AnnotationURLCitation(end_index=11091, start_index=10963, title='Procolipase Gene: No Association with Early-Onset Obesity or Fat Intake - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6444705/#:~:text=%5BPubMed%5D%20%5BGoogle%20Scholar%5D%20,Pro')
32. AnnotationURLCitation(end_index=11556, start_index=11386, title='Procolipase Gene: No Association with Early-Onset Obesity or Fat Intake - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6444705/#:~:text=%2A%201.Erlanson,4887.1992.tb02473.x.%20%5BDOI%5D%20%5BPubMed%5D%20%5BGoogle%20Scholar')
33. AnnotationURLCitation(end_index=11827, start_index=11688, title='Procolipase Gene: No Association with Early-Onset Obesity or Fat Intake - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6444705/#:~:text=Asp,s.%20%5BDOI%5D%20%5BPubMed%5D%20%5BGoogle%20Scholar')
34. AnnotationURLCitation(end_index=12083, start_index=11955, title='Procolipase Gene: No Association with Early-Onset Obesity or Fat Intake - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6444705/#:~:text=%5BPubMed%5D%20%5BGoogle%20Scholar%5D%20,Pro')
35. AnnotationURLCitation(end_index=12451, start_index=12281, title='Procolipase Gene: No Association with Early-Onset Obesity or Fat Intake - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6444705/#:~:text=%2A%201.Erlanson,4887.1992.tb02473.x.%20%5BDOI%5D%20%5BPubMed%5D%20%5BGoogle%20Scholar')
36. AnnotationURLCitation(end_index=12591, start_index=12452, title='Procolipase Gene: No Association with Early-Onset Obesity or Fat Intake - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6444705/#:~:text=Asp,s.%20%5BDOI%5D%20%5BPubMed%5D%20%5BGoogle%20Scholar')
37. AnnotationURLCitation(end_index=12936, start_index=12771, title='Procolipase Gene: No Association with Early-Onset Obesity or Fat Intake - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6444705/#:~:text=The%20colipase%20preproprotein%20,activation%20by%20trypsin%2C%20procolipase%20is')
38. AnnotationURLCitation(end_index=13541, start_index=13388, title='Procolipase Gene: No Association with Early-Onset Obesity or Fat Intake - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6444705/#:~:text=Several%20lines%20of%20evidence%20in,and%20fat%20intake%20in%20humans')
39. AnnotationURLCitation(end_index=14110, start_index=13974, title='CLPS colipase [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/1208#:~:text=catalytic%20domain%20of%20lipase%2C%20thereby,6%29%20See%20more')
40. AnnotationURLCitation(end_index=14550, start_index=14393, title='CLPS colipase [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/1208#:~:text=allows%20lipase%20to%20anchor%20noncovalently,provided%20by%20RefSeq%2C%20Nov%202011')
41. AnnotationURLCitation(end_index=15271, start_index=15058, title='C3028, Colipase from porcine pancreas, Lyophilized powder', type='url_citation', url='https://www.sigmaaldrich.com/SA/en/product/sigma/c3028?srsltid=AfmBOorwrF7JUkn9iJ5Q_C93_5VEpRrrQr8nHxzqQgpJPXr7y0V7G2Z5#:~:text=Description%20,an%20arrangement%20of%20protruding%20fingers')
42. AnnotationURLCitation(end_index=15635, start_index=15513, title='Crystallographic study of the structure of colipase and of the interaction with pancreatic lipase - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2142970/#:~:text=lacks%20well,Upon%20opening%20of%20the')
43. AnnotationURLCitation(end_index=15883, start_index=15731, title='A polymorphism in the gene encoding procolipase produces a colipase, Arg92Cys, with decreased function against long-chain triglycerides - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3684974/#:~:text=The%20more%20common%20arginine%2092,The%20addition%20of%20an%20extra')
44. AnnotationURLCitation(end_index=16245, start_index=16100, title='Crystallographic study of the structure of colipase and of the interaction with pancreatic lipase - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2142970/#:~:text=lacks%20well,a%20rather%20hydrophilic%20part%2C%20interacting')
45. AnnotationURLCitation(end_index=16606, start_index=16484, title='Crystallographic study of the structure of colipase and of the interaction with pancreatic lipase - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2142970/#:~:text=lacks%20well,Upon%20opening%20of%20the')
46. AnnotationURLCitation(end_index=16936, start_index=16814, title='Crystallographic study of the structure of colipase and of the interaction with pancreatic lipase - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2142970/#:~:text=lacks%20well,Upon%20opening%20of%20the')
47. AnnotationURLCitation(end_index=17472, start_index=17327, title='Crystallographic study of the structure of colipase and of the interaction with pancreatic lipase - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2142970/#:~:text=The%20colipase%20surface%20can%20be,Upon%20opening%20of%20the')
48. AnnotationURLCitation(end_index=17992, start_index=17853, title='Identification of amino acids in human colipase that mediate adsorption to lipid emulsions and mixed micelles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3642234/#:~:text=36%20on%20the%202,to%20mixed%20micelles%20is%20mediated')
49. AnnotationURLCitation(end_index=18357, start_index=18192, title='Identification of amino acids in human colipase that mediate adsorption to lipid emulsions and mixed micelles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3642234/#:~:text=purified%20recombinant%20colipase%20mutants%20and,residues%20Leu%2034%20and%20Leu')
50. AnnotationURLCitation(end_index=18497, start_index=18358, title='Identification of amino acids in human colipase that mediate adsorption to lipid emulsions and mixed micelles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3642234/#:~:text=36%20on%20the%202,to%20mixed%20micelles%20is%20mediated')
51. AnnotationURLCitation(end_index=18831, start_index=18658, title='Identification of amino acids in human colipase that mediate adsorption to lipid emulsions and mixed micelles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3642234/#:~:text=acrylamide%20quenching%20curves%20to%20characterize,to%20mixed%20micelles%20is%20mediated')
52. AnnotationURLCitation(end_index=19100, start_index=18961, title='Identification of amino acids in human colipase that mediate adsorption to lipid emulsions and mixed micelles - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3642234/#:~:text=36%20on%20the%202,to%20mixed%20micelles%20is%20mediated')
53. AnnotationURLCitation(end_index=19917, start_index=19760, title='Enzyme replacement therapy for pancreatic insufficiency: present and future - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/21753892/#:~:text=Enzyme%20replacement%20therapy%20for%20pancreatic,This%20treatment%20is%20safe')
54. AnnotationURLCitation(end_index=20220, start_index=20078, title='Isolated congenital lipase-colipase deficiency - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/6714581/#:~:text=Isolated%20congenital%20lipase,a%20history%20of%20passing%20oily')
55. AnnotationURLCitation(end_index=20691, start_index=20529, title='[Recent findings on pancreatic lipase and colipase] - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/6373427/#:~:text=hand%2C%20the%20enzyme%20is%20stabilized,hydrophobic%20region%20and%20by%20ionizable')
56. AnnotationURLCitation(end_index=21084, start_index=20931, title='Procolipase Gene: No Association with Early-Onset Obesity or Fat Intake - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6444705/#:~:text=Several%20lines%20of%20evidence%20in,and%20fat%20intake%20in%20humans')
57. AnnotationURLCitation(end_index=21878, start_index=21736, title='A polymorphism in the gene encoding procolipase produces a colipase, Arg92Cys, with decreased function against long-chain triglycerides - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3684974/#:~:text=yeast%20expression%20system%20and%20compared,Cys92%20fully')
58. AnnotationURLCitation(end_index=22305, start_index=22146, title='A polymorphism in the gene encoding procolipase produces a colipase, Arg92Cys, with decreased function against long-chain triglycerides - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3684974/#:~:text=triglycerides%20but%20only%20had%2050,lipase%20on%20an%20emulsion%20surface')
59. AnnotationURLCitation(end_index=22458, start_index=22306, title='A polymorphism in the gene encoding procolipase produces a colipase, Arg92Cys, with decreased function against long-chain triglycerides - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3684974/#:~:text=The%20more%20common%20arginine%2092,The%20addition%20of%20an%20extra')
60. AnnotationURLCitation(end_index=22967, start_index=22796, title='A polymorphism in the gene encoding procolipase produces a colipase, Arg92Cys, with decreased function against long-chain triglycerides - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3684974/#:~:text=that%20the%20Arg92Cys%20polymorphism%20decreases,development%20of%20type%202%20diabetes')
61. AnnotationURLCitation(end_index=23302, start_index=23131, title='A polymorphism in the gene encoding procolipase produces a colipase, Arg92Cys, with decreased function against long-chain triglycerides - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC3684974/#:~:text=that%20the%20Arg92Cys%20polymorphism%20decreases,development%20of%20type%202%20diabetes')
62. AnnotationURLCitation(end_index=23843, start_index=23761, title='Gosset', type='url_citation', url='https://gosset.ai/targets/colipase/#:~:text=Mechanism%20of%20Action')
63. AnnotationURLCitation(end_index=24271, start_index=24101, title='Delayed release pancrelipase for treatment of pancreatic exocrine insufficiency associated with chronic pancreatitis - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC2710383/#:~:text=preparations%20Porcine%20pancreatic%20enzymes%20are,be%20degraded%20in%20the%20stomach')
64. AnnotationURLCitation(end_index=24737, start_index=24560, title='Production of recombinant porcine colipase secreted by Pichia pastoris and its application to improve dietary fat digestion and growth of postweaning piglets - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/19194948/#:~:text=Production%20of%20recombinant%20porcine%20colipase,secretion%20cassette%20was%20constructed%20with')
65. AnnotationURLCitation(end_index=25077, start_index=24907, title='Procolipase Gene: No Association with Early-Onset Obesity or Fat Intake - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6444705/#:~:text=%2A%201.Erlanson,4887.1992.tb02473.x.%20%5BDOI%5D%20%5BPubMed%5D%20%5BGoogle%20Scholar')
66. AnnotationURLCitation(end_index=25663, start_index=25482, title='Colipase enhances hydrolysis of dietary triglycerides in the absence of bile salts - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC371277/#:~:text=Colipase%20enhances%20hydrolysis%20of%20dietary,and%20License%20information%20PMCID%3A%20PMC371277')
67. AnnotationURLCitation(end_index=26155, start_index=25993, title='[Recent findings on pancreatic lipase and colipase] - PubMed', type='url_citation', url='https://pubmed.ncbi.nlm.nih.gov/6373427/#:~:text=hand%2C%20the%20enzyme%20is%20stabilized,hydrophobic%20region%20and%20by%20ionizable')
68. AnnotationURLCitation(end_index=27134, start_index=26969, title='Procolipase Gene: No Association with Early-Onset Obesity or Fat Intake - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6444705/#:~:text=The%20colipase%20preproprotein%20,activation%20by%20trypsin%2C%20procolipase%20is')
69. AnnotationURLCitation(end_index=27263, start_index=27135, title='Procolipase Gene: No Association with Early-Onset Obesity or Fat Intake - PMC', type='url_citation', url='https://pmc.ncbi.nlm.nih.gov/articles/PMC6444705/#:~:text=%5BPubMed%5D%20%5BGoogle%20Scholar%5D%20,Pro')
70. AnnotationURLCitation(end_index=27704, start_index=27547, title='CLPS colipase [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/1208#:~:text=catalytic%20domain%20of%20lipase%2C%20thereby,provided%20by%20RefSeq%2C%20Nov%202011')
71. AnnotationURLCitation(end_index=28014, start_index=27857, title='CLPS colipase [Homo sapiens (human)] - Gene - NCBI', type='url_citation', url='https://www.ncbi.nlm.nih.gov/gene/1208#:~:text=catalytic%20domain%20of%20lipase%2C%20thereby,provided%20by%20RefSeq%2C%20Nov%202011')
72. AnnotationURLCitation(end_index=28169, start_index=28015, title='Gosset', type='url_citation', url='https://gosset.ai/targets/colipase/#:~:text=anchoring%20and%20stabilizing%20the%20enzyme,therapies%20targeting%20this%20molecule%20directly')

The CLPS gene (P04118) in humans encodes colipase, a small secreted protein that acts as a crucial cofactor for pancreatic lipase, enabling efficient dietary fat digestion. Below is a comprehensive overview of its molecular function, biological processes, cellular localization, protein domains, interactions, and disease associations, with emphasis on recent and authoritative sources.

1. Key Concepts and Definitions

• Gene Name: CLPS (Colipase)
• Protein Product: Colipase (UniProt P04118)
• Gene Location: Chromosome 6: 35762759 - 35765088 (reverse strand)[12]
• Protein Length: 112 amino acids[7][5]
• Molecular Weight: ~11.95 kDa[7]

2. Molecular Function

• Enzyme Activator Activity: Colipase is an enzyme activator that binds to pancreatic lipase, stabilizing its active conformation and allowing it to function at the lipid-water interface[1][9][7].
• Lipid Binding: It increases the hydrophobic binding site of lipase, facilitating the hydrolysis of dietary triglycerides[1][3].
• Counteracts Bile Salts: Colipase prevents the displacement of lipase from fat droplets by bile salts, which would otherwise inhibit lipase activity[1][3][9].

3. Biological Processes

• Lipid Catabolic Process: Essential for the hydrolysis of dietary triglycerides into diglycerides, monoglycerides, and free fatty acids, enabling fat absorption in the intestine[1][5][7].
• Digestion and Absorption: Plays a central role in the digestion and absorption of dietary fats[1][7].
• Satiety Signaling: The peptide enterostatin, derived from procolipase, has been implicated in satiety signaling, suggesting a role in appetite regulation[1].

4. Cellular Localization

• Secreted Protein: Colipase is synthesized in pancreatic acinar cells and secreted into the intestinal lumen[1][5][7].
• Extracellular Region: Its functional site is the extracellular region (intestinal lumen), where it interacts with pancreatic lipase and dietary fats[7][9].

5. Protein Domains

• Signal Peptide: Amino acids 1–17 constitute a signal region, directing secretion[7].
• Colipase Domain: The mature protein is characterized by a colipase domain with five conserved disulfide bonds, conferring structural stability[3].
• No Transmembrane Regions: Colipase is not membrane-bound[7].

6. Known Interactions

• Pancreatic Lipase: The primary and essential interaction is with pancreatic triglyceride lipase (PNLIP), binding to its C-terminal, non-catalytic domain[1][3][9].
• Bile Salts: Colipase also interacts with bile acids, acting as a bridge between lipase and the lipid-water interface[3].
• Paralogs: CLPSL1 is a known paralog, but its function is less well characterized[1].

7. Disease Associations

• Pancreas Disease: Mutations or dysfunction in CLPS can contribute to pancreatic insufficiency and related digestive disorders[1].
• Johanson-Blizzard Syndrome: This rare genetic disorder, characterized by exocrine pancreatic insufficiency, has been associated with CLPS among other genes[1].
• Polymorphisms: A known polymorphism (Arg92Cys) in procolipase results in decreased function against long-chain triglycerides, potentially impacting fat digestion[11].
• No Direct Cancer Link: While CLPS is a pancreas-specific gene, there is no strong evidence directly linking it to pancreatic cancer in current literature[6].

8. Recent Developments and Research (2023–2024)

• No major paradigm-shifting discoveries regarding CLPS function or disease association have been reported in 2023–2024. The gene’s role in lipid digestion and its necessity for pancreatic lipase activity remain well established and unchanged in recent literature[1][7][9].
• Systems biology and proteomics studies continue to map protein-protein interaction networks, but CLPS’s primary role remains as a cofactor for lipase, with no new major interaction partners identified[2].

9. Expert Opinions and Analysis

• Essential for Fat Absorption: Experts consistently highlight CLPS as indispensable for efficient dietary fat absorption, with loss-of-function mutations leading to malabsorption syndromes[1][3][7].
• Potential Therapeutic Target: While not a direct drug target, understanding CLPS function is important for addressing pancreatic insufficiency and related digestive disorders.

10. Relevant Statistics and Data

• Expression: CLPS is highly and specifically expressed in pancreatic acinar cells[1][5].
• Variants: Three transcript variants encoding different isoforms have been identified[1].
• Protein Family: Colipase is part of a family of evolutionarily related proteins, with structural analogies to other lipid-interacting domains[3].

Key Sources:
- GeneCards (2024): [1] (https://www.genecards.org/cgi-bin/carddisp.pl?gene=CLPS) (accessed Nov 2025)
- UniProt (2024): [9] (https://www.uniprot.org/uniprotkb/P04118/entry) (accessed Nov 2025)
- DrugBank (2024): [7] (https://go.drugbank.com/polypeptides/P04118) (accessed Nov 2025)
- NCBI Gene (2024): [11] (https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=1208) (accessed Nov 2025)
- Wikipedia (2024): [3] (https://en.wikipedia.org/wiki/Colipase) (accessed Nov 2025)

For further details, see the cited sources above.

Citations

1. https://www.genecards.org/cgi-bin/carddisp.pl?gene=CLPS
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC4869170/
3. https://en.wikipedia.org/wiki/Colipase
4. https://pmc.ncbi.nlm.nih.gov/articles/PMC4959873/
5. https://www.neobiotechnologies.com/product/colipase-clps-4/
6. https://patents.google.com/patent/WO2000055320A1/en
7. https://go.drugbank.com/polypeptides/P04118
8. https://digitalcommons.usf.edu/context/etd/article/8104/viewcontent/Mohamed_usf_0206D_14282.pdf
9. https://www.uniprot.org/uniprotkb/P04118/entry
10. https://patents.google.com/patent/US20200155691A1/en
11. https://www.ncbi.nlm.nih.gov/gene?Db=gene&Cmd=DetailsSearch&Term=1208
12. https://www.proteomicsdb.org/proteomicsdb/
13. https://platform.opentargets.org/target/ENSG00000137392
14. https://www.medchemexpress.com/recombinant-proteins/clps-protein-human-sf9-his.html

The user is asking for a comprehensive research report on the CLPS gene in humans, which encodes colipase (P04118). Let me analyze the search results to create a detailed, well-cited report.

Let me start by understanding what I have:
- Multiple sources describing CLPS/colipase's function as a pancreatic lipase cofactor
- Information about its role in fat digestion
- Details on its structure, mechanism, and interactions
- Information about diseases and genetic variations
- Evolutionary and structural studies

Planning my report:
1. Title and opening summary
2. Gene and protein overview - basic information
3. Primary function and molecular mechanism
4. Structural characteristics and domains
5. Role in lipid digestion pathway
6. Tissue localization and expression regulation
7. Molecular interactions and complex formation
8. Evolutionary conservation
9. Associated diseases and clinical significance
10. Recent developments and research insights
11. Conclusion

Let me make sure I cite properly and create a narrative flow rather than using lists.

Key points to cover:
- CLPS encodes colipase
- It's a cofactor for pancreatic lipase
- Located on chromosome 6
- Expressed in pancreatic acinar cells
- Small protein (~10-12 kDa)
- Has conserved disulfide bonds
- Enables lipase to function in presence of bile salts
- Binds to C-terminal domain of lipase
- Has finger-like structures for lipid interaction
- Critical for fat digestion
- Generates enterostatin as byproduct
- Evolutionary conserved in vertebrates

I need to write at least 10,000 words. Let me start writing the report with proper structure and citations.

Colipase (CLPS): Molecular Function, Structure, and Role as a Pancreatic Lipase Cofactor

Summary of Key Findings: The CLPS gene encodes colipase, a critical 10-12 kilodalton protein cofactor that enables pancreatic lipase to hydrolyze dietary triglycerides in the presence of inhibitory bile salts within the small intestinal lumen[1][4][21]. Rather than possessing enzymatic activity itself, colipase functions as an adapter protein that anchors the lipase enzyme to the lipid-water interface, thereby preventing the enzyme's displacement by bile salts and dramatically enhancing fat digestion efficiency[1][5][13]. The protein is produced exclusively in pancreatic acinar cells and is secreted in equimolar ratios with pancreatic lipase, with the precursor form (procolipase) being activated in the intestine through proteolytic cleavage by trypsin, which simultaneously generates enterostatin, a pentapeptide with satiety-signaling properties[1][2][19]. This report comprehensively examines the molecular mechanisms of colipase function, its structural organization, its critical role in nutrient absorption pathways, its evolutionary conservation, and its clinical significance in metabolic disorders.

Gene Organization and Protein Expression

Chromosomal Localization and Gene Structure

The CLPS gene is located on the long arm of chromosome 6 at position 6q21-22 and encodes a three-exon gene contained within a single 3.3-kilobase BamHI restriction fragment[37]. The human colipase gene was first isolated from a cosmid library using a complementary DNA probe and demonstrates tissue-specific expression patterns controlled by regulatory elements in its 5'-flanking region[37]. The gene contains a TATA box, a GC box, and a notably conserved 28-base pair region that exhibits homology to the rat pancreatic-specific enhancer element, which is the primary driver of tissue-specific expression of the chloramphenicol acetyltransferase gene when transfected into pancreatic acinar cell lines[37]. These regulatory elements ensure that colipase expression is restricted almost exclusively to pancreatic acinar cells, reflecting the digestive function of this protein and preventing inappropriate expression in non-pancreatic tissues[1][37].

Tissue-Specific Expression and Regulation

Colipase is expressed exclusively in pancreatic acinar cells, suggesting tight regulation by tissue-specific elements that precisely control when and where the protein is synthesized[1][17]. The synthesis and secretion of colipase are substantially increased by dietary fats and the hormone secretin, indicating that the genes for both triglyceride lipase and colipase contain nucleotide elements responsive to these physiological signals[37]. This nutritional regulation is physiologically sensible, as the demand for both colipase and lipase increases proportionally with dietary fat intake, ensuring adequate enzyme production to match substrate availability[5][13]. The increased messenger RNA levels accompanying elevated enzymatic activity directly link gene expression to metabolic demand, demonstrating the coordinated regulation of lipid-digesting enzymes with dietary composition[37]. In pancreatic insufficiency states or following pancreatic stimulation with cholecystokinin, colipase levels vary in parallel with lipase levels, underscoring their coordinated biological roles[13][32].

Primary Function and Molecular Mechanism

The Core Function: Lipase Activation and Substrate Anchoring

The fundamental role of colipase is to restore and maintain the activity of pancreatic lipase under physiological conditions in the small intestine, particularly in the presence of bile salts that would otherwise completely inhibit the enzyme[1][2][5][21]. Pancreatic lipase is a highly efficient enzyme capable of hydrolyzing 70-90 percent of total dietary triglycerides into diglycerides, monoacylglycerols, and free fatty acids in the small intestine[13]. However, this remarkable catalytic activity is paradoxically and almost completely inhibited when bile salts (the amphipathic molecules that emulsify dietary lipids) reach concentrations above the critical micellar concentration, which is precisely the condition present in the post-prandial small intestinal lumen[5][8]. The bile salts achieve this inhibition by adhering to the surface of emulsified lipid droplets and displacing pancreatic lipase from the droplet surface where catalytic activity occurs[21][24]. Colipase counteracts this inhibition by binding simultaneously to both pancreatic lipase and the bile salt-lipid interface, thereby anchoring the lipase enzyme to the lipid-water interface and preventing its displacement[4][21].

The mechanism of colipase-mediated lipase activation involves a sophisticated interplay between the structural features of both proteins and the interfacial properties of lipid substrates. In the absence of substrate, colipase binds to the C-terminal, non-catalytic domain of pancreatic lipase with only modest affinity (dissociation constant approximately 10⁻⁶ molar at physiological concentrations), a binding that would be insufficient to maintain stable complex formation under the dilute conditions of the intestinal lumen[5][8]. However, upon lipid binding, conformational changes occur at the active site of pancreatic lipase that bring a surface loop, termed the lid domain, into contact with colipase, creating a second binding site for this cofactor[7][57]. This secondary interaction dramatically increases the affinity of the colipase-lipase complex to approximately 10⁻⁸ to 10⁻⁹ molar, a 1000-fold increase that explains why the complex remains stable and functional at the lipid-water interface[5][8]. The apparent dissociation constant for the colipase-lipase complex varies with substrate composition and bile salt concentration, with typical values of 22.8 nanomolar in the presence of tributyrin and 4 millimolar sodium taurodeoxycholate[36].

The Sequential Theory of Colipase Function

Two competing models have been proposed to explain the precise mechanism by which colipase enables lipase activity in the presence of bile salts, with the "sequential theory" receiving broader experimental support[5]. According to the sequential theory, colipase binds first to the lipid substrate at the triglyceride-water interface, a binding that is facilitated by the favorable interactions between the hydrophobic residues of colipase and the exposed lipid surface[5][8][16]. This initial colipase-substrate interaction essentially creates a docking platform to which pancreatic lipase can subsequently bind. One molecule of lipase then binds to one molecule of colipase at the substrate interface, and hydrolysis of triglycerides then proceeds at an accelerated rate[5][8][16]. The sequential theory is strongly supported by the observation that in the absence of substrate, there is only negligible binding of lipase and colipase at physiological concentrations of these proteins in the presence of bile salts[5]. Furthermore, colipase binding to triglyceride substrate, while not exceptionally strong in isolation, becomes substantially strengthened upon lipase binding, forming the high-affinity ternary complex[5][8].

An alternative model, which has not gained widespread acceptance, proposes that lipase, colipase, and bile salt mixed micelles form a complex that binds to the triglyceride surface as a unified entity[5]. While this model cannot be entirely excluded based on available data, the sequential model explains the kinetic observations more parsimoniously and is more consistent with structural studies showing that colipase and lipase bind to each other with higher affinity when the substrate interface is present[5][8][16].

Protein Structure and Molecular Architecture

Overall Three-Dimensional Structure and Stabilizing Disulfide Bonds

Colipase is a small protein with a molecular mass of approximately 10-12 kilodaltons, containing between 94 and 105 amino acid residues depending on species variation[1][2][21]. The most distinctive structural feature of colipase is its stabilization by an extended network of five highly conserved disulfide bonds that traverse the entire three-dimensional structure, reticulating four finger-like loops that protrude from a central core[7][23][57]. These five disulfide bridges are crucial for protein stability and structural integrity, and they are conserved across diverse vertebrate species from fish to mammals, indicating that this structural organization is essential for colipase function[26][45]. The protein's three-dimensional structure is notably compact and relatively flat compared to typical globular proteins, a morphology that is fundamentally shaped by the extensive disulfide bond network rather than by extensive alpha-helical or beta-sheet secondary structures[57]. This architectural organization confers upon colipase a structure topologically comparable to snake toxins, a structural analogy that was not fully appreciated until crystallographic studies became available[7][23].

The five disulfide bonds in colipase are positioned at characteristic locations within the protein sequence and three-dimensional structure, and their formation and reduction are critical biochemical processes. Early crystallographic work firmly established the positions of these disulfide connections, confirming that the structure originally proposed by Chaillan and colleagues was correct[57]. The disulfide bonds stabilize the four finger-like loops at their base and throughout their length, preventing the protein from undergoing conformational collapse or unfolding under the alkaline pH and ionic conditions present in the small intestinal lumen[57]. The remarkable stability conferred by these extensive disulfide bonds is reflected in colipase's heat stability—the protein maintains its biological activity under heating conditions that would denature most other digestive proteins, a property that was historically used to help identify and purify colipase from pancreatic secretions[1][2].

The Four-Finger Architecture and Lipid-Binding Surfaces

The four finger-like loops that emerge from the colipase scaffold represent the most functionally significant structural elements for lipid interaction and substrate recognition[7][23][57]. The tips of these fingers contain the highest concentration of hydrophobic amino acid residues, creating a defined hydrophobic plateau that presumably forms the interfacial binding site for lipid molecules[7][23][57]. The first finger contains hydrophobic residues at positions such as leucine 16 and methionine 18 (or leucine 18 in pig colipase)[56]. The second finger harbors hydrophobic residues including alanine 33 (or isoleucine 33 in the pig), leucine 34, and leucine 36[56]. The third finger contains tyrosine residues at positions 55 and 59, which contribute to both the hydrophobic character of the interface and hydrogen bonding potential[36][56]. The fourth finger contains isoleucine residues at positions 75 and 79, and valine at position 76, creating a notably hydrophobic region[20][56].

These finger-tips are relatively mobile structures compared to the rest of the colipase molecule, and this flexibility is crucial to the protein's function[57]. The mobility of the finger regions allows colipase to adapt its conformation when binding to different types of lipid aggregates, whether triglyceride droplets with different surface properties or mixed micelles of varying lipid and bile salt composition[59]. Computational modeling and simulation studies demonstrate that although colipase has a single energetically favorable direction of interaction with a lipid interface, it does not bind in a stereochemically fixed way but rather oscillates between different positions, with different fragments of the sequence inserting into the interface either simultaneously or at different times[59]. This plasticity in finger positioning is a crucial adaptive feature that allows colipase to function across the range of different lipid aggregate compositions encountered during the digestive process[59].

The Lipase-Binding Surface and Polar Interactions

In contrast to the hydrophobic finger regions that interact with lipids, the opposite side of the colipase molecule presents a relatively hydrophilic surface that directly interacts with the C-terminal domain of pancreatic lipase[7][23][57]. The interaction between colipase and the C-terminal domain of pancreatic lipase is stabilized by eight hydrogen bonds and approximately eighty van der Waals contacts in the binary complex formed in the absence of substrate[57]. Upon the opening of the lid domain of lipase that occurs during substrate binding and interfacial activation, three additional hydrogen bonds and approximately twenty-eight additional van der Waals contacts are formed, increasing the total interaction strength and explaining the higher apparent affinity of the colipase-lipase complex in the presence of lipid[57].

A particularly critical interaction involves an ion pair between lysine 400 on pancreatic lipase and glutamic acid 45 on colipase—residues that are strictly conserved among diverse vertebrate species, indicating that this interaction is functionally essential[28]. Mutation of this ion pair to prevent its formation through charge neutralization or inversion leads to lipase-colipase complexes with markedly reduced affinity and poor catalytic efficiency, particularly in the presence of bile salt micelles[28]. The ion pair appears to play a critical role in stabilizing the correct active conformation of the lipase-colipase-micelle ternary complex by contributing to proper orientation of colipase relative to lipase and facilitating correct opening of the lipase lid[28]. Furthermore, glutamic acid 15 of colipase directly contacts the lid domain of lipase in its open conformation, and mutation of this residue to arginine reduces colipase activity by 175-fold, though the mutant colipase remains nearly as effective at anchoring lipase to mixed emulsions[25]. This striking observation indicates that colipase has a function in lipolysis beyond simply anchoring lipase to an interface—it actively stabilizes the lid domain of lipase in the open conformation, thereby facilitating hydrolysis[25].

Role in Lipid Digestion and Intestinal Absorption

Integration into the Multi-Stage Fat Digestion Process

The digestion of dietary fats is a multi-stage process that begins in the mouth with lingual lipase and continues in the stomach with gastric lipase, but the majority of fat digestion (70-90 percent of total triglyceride hydrolysis) occurs in the duodenum and proximal jejunum of the small intestine through the action of pancreatic lipase with its essential colipase cofactor[13][24][32]. The stomach is the major site of mechanical emulsification of dietary fat, which is an important prerequisite for efficient hydrolysis by pancreatic lipase, and this emulsification is facilitated by the diacylglycerols and fatty acids produced as a result of the action of acid lipases in the stomach[13]. The lipid emulsion enters the small intestine as fine lipid droplets with diameters of less than 500 nanometers, presenting an enormous surface area for pancreatic lipase and colipase to act upon[13].

The combined actions of bile from the liver and pancreatic juice markedly alter the chemical composition of the lipid emulsion in the upper part of the small intestine, creating the specific chemical environment in which colipase must function[13][32]. Pancreatic lipase functions at the interface between the oil phase and the aqueous phase, and hydrolyzes mainly the sn-1 and sn-3 positions of triglyceride molecules to release monoacylglycerols and fatty acids[13]. Further hydrolysis of monoacylglycerols by pancreatic lipase results in the formation of glycerols and additional fatty acids, though pancreatic lipase shows lower activity against monoglycerides than against triglycerides[13].

Interfacial Activation and the Importance of Substrate Interfaces

Pancreatic lipase exhibits dramatically increased activity when presented with water-insoluble substrates at an oil-water interface, a phenomenon termed interfacial activation that is characteristic of lipases but not of other hydrolases[49]. This interfacial activation depends critically on the conformational change in lipase that brings the lid domain into contact with the active site, exposing both the catalytic site and creating a large hydrophobic binding pocket[49]. When X-ray crystallographic analysis is performed on lipases at oil-water interfaces, it reveals that the major surface loop covering the active site undergoes dramatic movement, shifting from a closed conformation that prevents substrate access to an open conformation that permits catalysis[49]. Pancreatic lipase mutants with deletions in the lid domain show markedly decreased activity against both tributyrin and triolein compared with wild-type pancreatic lipase, and these mutants do not show a preference for water-soluble versus water-insoluble substrates[49]. Importantly, these lid-deficient mutants retained significant activity against tributyrin (a small triglyceride), but not against triolein (a long-chain triglyceride), when assayed in the absence of colipase, demonstrating that the lid domain is essential for interfacial activation and interfacial binding but not absolutely required for catalysis against monomeric substrates[49].

Colipase Function in the Absence of Bile Salts

An important physiological observation is that colipase can enhance the hydrolysis of dietary triglycerides even in the absence of bile salts, demonstrating that colipase possesses functions beyond merely counteracting the inhibitory effects of bile salts[16]. Long-chain triglycerides emulsified with phosphatidylcholine were found to be hydrolyzed very slowly by pancreatic lipase alone, as if the surface layer of phospholipids enveloping the triglycerides impeded the action of the enzyme[16]. Colipase enhanced triglyceride hydrolysis several-fold, both when added before or after the lipase in in vitro systems[16]. Hydrolysis became even more rapid when the emulsion was first incubated with pancreatic phospholipase A2, which partially degrades the phospholipid coating[16]. Importantly, hydrolysis of long-chain triglycerides was severely impeded when other proteins were added to the system, probably because they adsorbed to the oil-water interface of the emulsion droplets, and colipase was found to enhance hydrolysis several-fold in a dose-dependent manner even in the absence of bile salts, relieving the inhibition caused by adsorbed proteins[16].

Most dietary triglycerides are presented for intestinal digestion in emulsions covered by proteins and phospholipids derived from dietary sources and biliary secretion[16]. These emulsions would be hydrolyzed slowly by pancreatic lipase alone, but through the action of the lipase in stomach contents, pancreatic phospholipase, and the lipolysis-promoting effects of colipase, these triglycerides can be rather efficiently hydrolyzed even in the absence of bile salts[16]. This finding indicates that colipase has evolved to solve multiple barriers to lipid hydrolysis in the intestinal lumen, not merely the one problem posed by bile salt inhibition[16].

Molecular Interactions and Complex Formation with Pancreatic Lipase

Binding Specificity and the C-Terminal Domain Recognition

The interaction between colipase and pancreatic lipase is highly specific, with colipase binding exclusively to the C-terminal, non-catalytic domain of pancreatic lipase and not to the N-terminal catalytic domain[7][15][18][23]. Determination of the three-dimensional structure of pancreatic lipase has revealed the presence of two functionally distinct domains: an amino-terminal domain at residues 1-336 containing the active site and catalytic triad, and a carboxy-terminal domain at residues 337-449[7][23]. Procolipase (the precursor form of colipase) binds exclusively to the C-terminal domain of lipase, with no direct interaction with the catalytic N-terminal domain[7][23]. Remarkably, no conformational change in the lipase molecule is induced by the binding of colipase to the C-terminal domain in the binary complex formed in the absence of substrate[7][23]. This lack of conformational change in the lipase upon initial colipase binding is physiologically important, as it suggests that colipase does not dramatically perturb lipase structure in the absence of substrate but rather primes the enzyme for activation upon substrate encounter.

The recombinant expression of isolated N-terminal and C-terminal domains of pancreatic lipase in insect cells revealed that whereas the C-terminal domain retains its function of colipase binding, the N-terminal domain appears to be unable to ensure catalysis[15]. The lack of activity of the recombinant N-terminal domain could result either from partially incorrect folding or from an incapacity to function by itself as a separate entity[15]. These results suggest that although both domains are structurally well-defined, the two domains of pancreatic lipase behave differently when expressed as separate entities, indicating that the two-domain architecture of lipase is not merely compartmentalizing function but rather the domains are functionally interdependent in the complete enzyme[15].

The Lipase-Colipase Complex at the Substrate Interface

In solution, in the absence of detergent micelles or lipid substrates, colipase binds almost exclusively to the C-terminal domain of lipase[18]. However, when substrate is present in the form of mixed micelles of bile salts and fatty acids or lipid droplets, a dramatic increase in binding affinity occurs, with the formation of a high-affinity complex consisting of substrate, colipase, and lipase[5][8][18]. The classical two-step mechanism proposes that colipase first binds to the substrate, and this binding then facilitates the binding of lipase to form the active ternary complex[5][8]. The alternative model, which has not gained wide acceptance, suggests that the complex might form in the aqueous phase and then bind as a unit to the substrate[5].

Gel filtration studies provide evidence consistent with the two-step model by demonstrating that colipase exhibits strong binding to phosphatidylcholine and fatty acid mixed bile salt micelles when applied in a sample on gel filtration columns eluted with various buffers[53]. High affinity binding of lipase to colipase was observed at protein concentrations as low as 10⁻⁸ molar on columns equilibrated with oleic acid-taurodeoxycholate mixed micelles, whereas this binding did not take place on columns equilibrated with simple bile salt or mixed phosphatidylcholine-cholesterol-bile salt micelles[53]. Colipase alone exhibited strong binding to phosphatidylcholine and fatty acid mixed bile salt micelles when applied on columns eluted with pure bile salts, while lipase did not bind under these conditions, providing evidence that colipase can indeed bind substrates in the absence of lipase[53].

Structural Studies of the Lipase-Colipase Complex

The first crystal structure of the pancreatic lipase-procolipase complex was determined at 3.04 angstrom resolution and revealed crucial details about the geometric and chemical interactions between these two proteins[7][23]. The structure showed that procolipase indeed consists of three prominent "fingers" extending from a central core, a structure topologically comparable to snake toxins, with the tips of the fingers containing most of the hydrophobic amino acids and presumably forming the interfacial binding site for lipids[7][23]. Lipase binding occurs at the opposite side to this lipid-binding site and involves polar interactions, reinforcing the concept that colipase is an adapter protein with two distinct surfaces—one for interacting with lipid substrates and one for binding the lipase enzyme[7][23].

More recent crystallographic studies at 2.4 angstrom resolution, utilizing a covalently inhibited pancreatic lipase by a phosphonate inhibitor, provided an even more detailed description of the colipase structure and its interactions with lipase[57]. These studies confirmed the proposed disulfide bond connections and revealed that colipase lacks well-defined secondary structure elements and is stabilized mainly by the extended network of five disulfide bridges[57]. The colipase surface can be divided into a relatively hydrophilic part interacting with lipase and a more hydrophobic part formed by the tips of the fingers that interact with lipid substrates[57].

Enterostatin: The Peptide Product of Procolipase Activation

Proteolytic Generation and Biochemical Characterization

When procolipase is activated in the small intestinal lumen by the protease trypsin, the cleavage results in the production of two products in equimolar amounts: mature colipase and a pentapeptide designated enterostatin[2][19][22]. The pentapeptide enterostatin has the sequence Val-Pro-Asp-Pro-Arg (VPDPR), and is produced as a direct result of trypsin cleaving a peptide bond at the N-terminus of procolipase to generate the active colipase[19][22]. This coupled generation of both a functional enzyme cofactor and a bioactive peptide signal from a single precursor molecule represents an elegant example of enzymatic processing generating two distinct physiological signals from a single gene product[19][22].

Satiety Signaling and Nutritional Regulation of Food Intake

A particularly fascinating aspect of enterostatin is its biological activity as a satiety signal, suggesting that colipase participates not only in the biochemical process of fat digestion but also in the neural and endocrine signaling that regulates total energy intake[1][9][12]. The time course of feeding, grooming, exploration, and sleeping behaviors has been measured following treatment with enterostatin in experimental animals, with the peptide injected intraperitoneally prior to presenting food[9]. Enterostatin did not delay the onset of feeding but shortened the time spent eating compared with saline-injected controls[9]. Conversely, grooming activity appeared earlier following enterostatin treatment, activity was reduced, and resting behavior occurred earlier with this peptide[9]. For the first hour following enterostatin treatment, eating represented 20.8 percent of the time, grooming 9.2 percent, activity 18.3 percent, and rest or sleep 47.2 percent, with drinking making up the remaining 4.4 percent[9]. In contrast, saline-injected animals ate for 27.1 percent of the time, groomed for 12.4 percent, were active 28.5 percent of the time, had sleep or rest time equal to 27.9 percent, and drank for 4.1 percent of the time[9]. These studies support the concept that enterostatin decreases food intake by producing early satiety[9].

Most remarkably, enterostatin has been shown to selectively inhibit fat intake during normal feeding and in experimental paradigms involving dietary choice[12][22]. After starvation for 18 hours, rats given a free choice of a low-fat diet containing 5.2 percent fat by weight and a high-fat diet containing 17.8 percent fat by weight in separate containers received injections of 200 nanograms of VPDPR (enterostatin) into the lateral ventricle of the brain[22]. The rats selectively decreased the intake of the high-fat diet by 45 percent (p less than 0.005), while the intake of the low-fat diet was unaffected compared with saline injection controls[22]. Remarkably, VPDP (a peptide lacking the terminal arginine) after intracerebroventricular injection had totally lost the selective effect on the consumption of high-fat versus low-fat diets[22]. It is suggested that enterostatin formed during fat digestion from pancreatic procolipase may provide a feedback signal for the intake of lipids, creating a nutrient-specific satiety mechanism[22]. This discovery implicates colipase in a previously unrecognized regulatory pathway controlling macronutrient-specific appetite and energy homeostasis[22].

Evolutionary Conservation and Vertebrate Diversity

Ancient Origin and Vertebrate Presence

The evolutionary history of colipase extends remarkably far back in vertebrate evolution, preceding even the development of an organized exocrine pancreatic gland[26][45]. In an evolutionary study utilizing criteria including restoration of lipase activity inhibited by bile salts, cross-reactivity with antisera to mammalian colipases, and demonstration of the characteristic heat-stable, low-molecular-weight protein properties, the presence of colipase has been verified in the exocrine pancreatic cells of highly ancient fish species including hagfish (Myxine glutinosa), ratfish (Chimaera monstrosa), rayfish (Raja radiata), Greenland shark (Somnius microcephalus), and dogfish (Squalus acanthius)[26][45]. No colipase activity could be found in the gastric juice of crayfish (Pacifastacus leniusculus), a crustacean lacking a true exocrine pancreas[26][45]. These results indicate that colipase evolved in the vertebrates before the organized exocrine pancreatic gland was established and occurred simultaneously with the appearance of bile salts and bile alcohols in vertebrate physiology[26][45].

This ancient evolutionary origin is particularly striking because it demonstrates that colipase co-evolved with the bile salt-mediated lipid solubilization system as fundamental adaptations enabling efficient dietary fat absorption in aquatic and subsequently terrestrial vertebrates[26][45]. The conservation of colipase across such vast evolutionary distances—spanning from primitive jawless fish to modern mammals—strongly suggests that the molecular mechanisms of colipase function determined in mammalian systems are directly applicable to understanding lipid digestion across the vertebrate phylogeny[26][45].

Sequence Conservation and Cross-Species Functionality

When the complete amino acid sequence of colipase from diverse vertebrate species has been compared, the NH2-terminal sequencing of purified colipase from the common stingray (Dasyatis pastinaca) exhibits more than 55 percent amino acid identity with those of mammalian, avian, and marine colipases[2][33]. This level of sequence identity across such evolutionarily distant species is remarkably high, particularly considering that these sequences encompass millions of years of independent evolution[2][33]. The fact that colipase is indeed a universal lipase cofactor across diverse vertebrate species, as demonstrated by the ability of colipase from one species to partially activate lipase from another species, suggests that there is conservation of the colipase-lipase interaction site despite sequence divergence[2][33].

Stingray pancreatic lipase (SPL) was found to be activated by all pure pancreatic colipases tested, independent of their species origins, though mammalian and avian colipases were less effective activators of the marine enzyme than was the marine colipase from the same species[2][33]. The apparent dissociation constants of different lipase-colipase complexes vary with the species combination, with the stingray colipase and stingray lipase combination showing a lower apparent Kd (1.2 × 10⁻⁹ molar) compared with the stingray lipase in complex with turkey, chicken, or dromedary colipases (ranging from 2.2 to 3.9 × 10⁻⁹ molar)[2][33]. The kcat/Kd ratios indicating catalytic efficiency are highest (2073 s⁻¹M⁻¹ × 10⁻⁹) for the stingray colipase-stingray lipase combination, compared with lower efficiency ratios when colipases from other species were combined with stingray lipase[2][33]. These observations support the principle that optimal colipase function occurs with lipase from the same species, likely due to coevolutionary refinement of the interaction surface, yet cross-species activation demonstrates sufficient conservation of the critical interaction domain to permit heterologous enzyme-cofactor combinations[2][33].

Structural Homologies and Broader Protein Family Relationships

A structural analogy has been discovered between colipase and a domain in the developmental protein Dickkopf, based on sequence analogy and homology modeling, though whether this structural similarity implies a common function (such as lipid interaction) remains to be clarified[10]. Structural analogies have also been recognized between the pancreatic lipase C-terminal domain (the colipase-binding domain), the N-terminal domains of lipoxygenases, and the C-terminal domain of alpha-toxin, all of which are non-catalytic domains important for interaction with membranes[10]. It has not been established whether these non-catalytic domains in lipoxygenases or alpha-toxin are also involved in protein cofactor binding as is the case for pancreatic lipase[10]. The structural similarities suggest evolutionary relationships among apparently distinct protein families, though the functional significance of these architectural homologies awaits further investigation[10].

Associated Genetic Disorders and Clinical Manifestations

Pancreatic Colipase Deficiency and Congenital Absence

Isolated congenital combined pancreatic lipase and colipase deficiency is an exceptionally rare genetic disorder, with fewer than a dozen confirmed cases described in the medical literature[51]. A notable case of a five-year-old child with isolated combined pancreatic lipase and colipase deficiency presented with a history of passing oily stools since birth, and pancreatic stimulation tests showed that both lipase and colipase activities were less than 2 percent of normal control values[51]. Despite the total lack of both enzymes, the patient's fat absorption coefficient was 50 percent, indicating that residual fat absorption occurs through alternative enzymatic mechanisms not dependent on pancreatic lipase and colipase[51]. Fat absorption coefficient increased to 82 percent with pancreatic enzyme supplementation, demonstrating the therapeutic value of enzyme replacement therapy in this condition[51]. This case represented the first confirmed report of congenital combined lipase and colipase deficiency[51].

Johanson-Blizzard Syndrome and Pancreatic Insufficiency

Johanson-Blizzard syndrome (JBS) is an extremely rare genetic disorder affecting multiple organ systems that includes exocrine pancreatic insufficiency as a primary manifestation[31][34]. Although JBS is most commonly caused by mutations in the UBR1 gene encoding ubiquitin E3 ligase rather than directly in the CLPS gene, the pancreatic exocrine insufficiency phenotype of JBS can include deficiency of both pancreatic lipase and colipase[31][34]. The disease presents with hallmark features including aplasia or hypoplasia of the nasal alae, pancreatic exocrine insufficiency presenting in the newborn or young infant with failure to thrive, oily stools, and fat-soluble vitamin malabsorption[31][34]. Additional features include dental anomalies (oligodontia or hypodontia of permanent teeth present in more than 90 percent of cases), sensorineural hearing loss (approximately 75 percent of cases), and short stature (approximately 60 percent of cases)[31][34]. The prevalence of JBS in Europe has been estimated to be around 1 in 250,000 live births, making it an extraordinarily rare condition[31][34].

The UBR1 protein is essential for several chemical processes in the body and is normally found in high levels in the exocrine cells of the pancreas, with deficient levels of functional UBR1 protein ultimately resulting in the findings and physical features of JBS through mechanisms that remain poorly understood[31][34]. Diagnosis is based on identification of the pathognomonic combination of congenital or infantile exocrine pancreatic insufficiency with other characteristic anomalies such as aplasia or hypoplasia of the nasal alae, with genetic screening of UBR1 confirming the diagnosis[31][34]. Treatment includes oral administration of exogenous pancreatic enzymes and nutritional support with high-calorie diet containing 30-40 percent calories from fat, along with lipase, fat-soluble vitamins, and mineral supplementation[31][34].

Pancreatic Lipase Deficiency and Steatorrhea

Pancreatic lipase deficiency is a rare autosomal recessive disorder characterized by exocrine pancreatic failure[54]. Patients with pancreatic lipase deficiency typically exhibit oily or greasy stools (steatorrhea) from infancy or early childhood, in the complete absence of discernible pancreatic disease[54]. Duodenal content analyses consistently show a significant decrease in pancreatic lipolytic activity in these patients, yet remarkably, failure to thrive has not been observed in affected individuals, suggesting that alternative mechanisms for fat absorption can partially compensate for the enzymatic deficiency[54]. The condition is often characterized by voluminous stools despite the steatorrhea, yet patients' growth and overall state of health are reported to be good, likely reflecting the partial compensation by other lipase enzymes (such as gastric lipase and gastric lipase-related proteins) and alternative fat absorption mechanisms[54].

Regulation of Expression and Pancreatic Adaptation

Hormone and Nutrient-Dependent Regulation

The regulation of colipase and pancreatic lipase expression is intimately linked to dietary composition and pancreatic hormonal signals[14][37]. In studies of insulin-deficiency and insulin-resistance obese Zucker rats (fa/fa), the activity of lipase and colipase in pancreatic acinar tissue was increased by approximately 100 percent following injection of streptozotocin (a diabetes-inducing toxin), with the increase in colipase activity occurring 3 days later than that of lipase[14]. At the same time, amylase activity was decreased by 98 percent, indicating selective upregulation of lipid-digesting enzymes and downregulation of carbohydrate-digesting enzymes in the diabetic state[14]. Correction of the diabetic state with insulin (1 unit per 100 grams of body weight per day) reversed the activities of these enzymes to their pre-diabetic levels, demonstrating that the altered enzyme pattern is insulin-dependent[14]. Administration of high-dose insulin (6 units per 100 grams of body weight per day) to normal Sprague-Dawley rats increased the activity of amylase as well as lipase and colipase, whereas injection of glucagon (0.3 milligrams per 100 grams of body weight per day) decreased the activity of amylase and colipase but had no significant effect on lipase activity[14]. These findings indicate that pancreatic lipase and colipase activity are substantially increased following either insulin deficiency or insulin resistance in rats through a mechanism related to the changed levels of circulating insulin[14].

In obese Zucker rats (fa/fa), the activity of lipase and colipase at the onset of obesity (5 weeks of age) was lower than in their lean littermates (fa/o), but thereafter the activity of the two proteins increased with age, being 40 percent higher in the fa/fa rat than in the fa/o rat at age 7 weeks[14]. During the same period, amylase activity decreased[14]. These results suggest that pancreatic adaptation to metabolic states involves coordinated adjustment of enzyme expression patterns, with preferential upregulation of lipid-digesting enzymes in situations of altered carbohydrate and lipid metabolism[14].

Transcriptional Control and Promoter Elements

The tissue-specific expression of colipase is controlled by specific promoter elements in the gene's 5'-flanking region[37]. A 28-base pair region in the 5'-flanking DNA of the human colipase gene shows homology to the rat pancreatic-specific enhancer and specifically directs tissue-specific expression of reporter genes in pancreatic acinar cell lines[37]. This 28-base pair region specifically binds to transcription factors in nuclear extracts derived from pancreatic tissue, suggesting that the regulation of colipase expression involves interaction of pancreas-specific transcription factors with defined promoter elements[37]. The same construct containing this promoter region is inactive in hepatic (HEPG2), muscle (C2C12), and monkey (COS-1) cell lines, demonstrating the strict tissue-specific nature of the regulatory elements[37].

Adsorption to Lipid Interfaces and Molecular Interactions

Identification of Residues Mediating Interface Adsorption

To directly identify which specific amino acids in the hydrophobic surface of colipase influence adsorption to lipid interfaces, researchers systematically substituted alanine or tryptophan at residues implicated in adsorption[36][56]. Colipase mutants were expressed and purified, and their ability to restore activity to pancreatic lipase in the presence of bile salts was characterized[36][56]. The functions of L16A, Y55A, I79A, and F84A colipase were most impaired, with activities ranging from 20 to 60 percent of wild-type colipase[36][56]. Tryptophan mutants were characterized by measuring their fluorescence properties in the absence and presence of bile-salt-oleic acid mixed micelles[36][56]. Steady-state emission spectra were used to determine peak shift and the I₃₃₀/I₃₅₀ ratio, and acrylamide quenching curves were obtained to characterize the environment of the residues[36][56].

The analysis revealed that the adsorption of colipase to interfaces involves residues residing in defined locations within the colipase structure: residues Leu 34 and Leu 36 on the second loop, Tyr 55 and Tyr 59 on the third loop, and Ile 75 and Ile 79 on the fourth loop[36][56]. The analysis confirmed that Phe 84 is not part of the adsorption surface and likely stabilizes the conformation of colipase[36][56]. Importantly, the results provided strong support for an essential role of Tyr 55 in colipase adsorption to mixed micelles, contrary to the predictions of earlier computational modeling that had suggested Tyr 55 was on the hydrophilic side of colipase opposite the hydrophobic fingers[36][56]. These molecular-level analyses have elucidated the specific chemical basis of colipase-lipid interactions, providing a mechanistic understanding of how this small protein bridges the enzyme-substrate interface[36][56].

Adsorption to Different Lipid Aggregate Types

The adsorption behavior of colipase and pancreatic lipase onto different types of lipid monolayers has been investigated using Langmuir trough and pendant drop experiments, along with atomic force microscopy imaging[11]. When comparing digalactosyldiacylglycerol (DGDG) and dipalmitoylphosphatidylcholine (DPPC) monolayers at the air-water interface, a DGDG interface was found to be more resistant to the adsorption of bile salts, colipase, and lipase compared to that of DPPC[11]. Atomic force microscopy images showed that the adsorption of bile salts into a DPPC monolayer decreased the size of the liquid condensed domains, while there was no visible topographical change for DGDG systems[11]. The results showed that colipase and lipase adsorbed exclusively onto the mixed DPPC-bile salt regions and not onto the DPPC condensed phase[11].

When colipase and lipase were in excess, they fully covered the mixed DPPC-bile salt regions, but the colipase and lipase coverage on the mixed DGDG-bile salt monolayer was incomplete and discontinuous[11]. It was postulated that bile salts adsorbed into the DPPC monolayers fill the gaps between the lipid headgroups and space out the lipid molecules, making the lipid hydrocarbon tails more exposed to the surface and creating hydrophobic patches suitable for the binding of colipase and lipase[11]. In contrast, bile salts adsorb less easily into the DGDG monolayer because DGDG possesses a larger headgroup with strong intermolecular interactions and the ability to adopt different orientations at the interface, resulting in fewer hydrophobic patches of sufficient size to accommodate the colipase[11]. These results have reinforced the hypothesis that the interfacial molecular packing of lipids at the oil-water interface influences the adsorption of bile salts, colipase, and lipase, which in turn impacts the rate of lipolysis[11].

Inhibition and Regulation by Bile Salts and Other Factors

Mixed Micelle-Mediated Inhibition of Lipase Activity

Mixed dihydroxy bile salt-phosphatidylcholine micelles can inhibit the hydrolysis of emulsified long-chain triglycerides by pancreatic lipase and colipase at micelle concentrations of 10⁻⁸ to 10⁻⁹ molar[50]. The degree of inhibition depended principally on the species of bile salt present, with taurochenodeoxycholate being more inhibitory than taurodeoxycholate, taurodeoxycholate more inhibitory than tauroursodeoxycholate, and tauroursodeoxycholate more inhibitory than taurocholate[50]. In the absence of bile salts, phosphatidylcholine liposomes alone were not inhibitory over the physiological time range studied[50]. Bile salt solutions containing phosphatidylethanolamine or sphingomyelin also inhibited lipase activity, whereas those containing oleyl alcohol, oleyl aldehyde, oleic acid, and lyso-phosphatidylcholine did not[50].

Mixed bile salt-phospholipid micelles caused a marked decrease in the binding of lipase and colipase to the triglyceride substrate and displaced these proteins into the aqueous phase[50]. Full reversal of inhibition occurred in the presence of phospholipase A2, which hydrolyzes the phospholipids to lysolecithin and fatty acids, demonstrating that the phospholipid component is critical for the inhibitory effect[50]. The results suggest that colipase binds to certain bile salt-phospholipid associations independent of whether the aggregates are located at the surface of a triglyceride particle or in the bulk aqueous phase as mixed micelles[50]. This mechanism of inhibition by mixed micelles represents a regulation point that ensures lipase activity is appropriately controlled within the physiological range of bile salt and phospholipid concentrations[50].

Evolutionary Variation and Fish Lipase-Colipase System Divergence

Species-Specific Lipase-Colipase Interactions in Fish

A fascinating example of evolutionary divergence in the lipase-colipase system has been observed in certain fish species, particularly in cartilaginous fish such as the smooth-hound (Mustelus mustelus)[29]. The recently purified enzyme from smooth-hound shows no dependence on bile salts or colipase, representing a remarkable departure from the classical mammalian system[29]. Structural modeling of the smooth-hound digestive lipase revealed several dissimilarities when analyzing amino acids corresponding to those involved in human pancreatic lipase binding to colipase[29]. Several residues known to be involved in human pancreatic lipase binding to colipase are conserved in the smooth-hound digestive lipase, including Asn241, Asp248, and Lys400[29]. However, Ile402, which belongs to the C-terminal domain of human pancreatic lipase and interacts with Arg65 of colipase, is substituted by Leu400 in the smooth-hound lipase[29]. Furthermore, Tyr404, known to be a key residue for human pancreatic lipase binding to colipase, is replaced by Asn in the smooth-hound lipase[29].

This Tyr404 to Asn substitution was previously observed in the annular and red seabream digestive lipases, which are also independent of the classical bile salt-colipase system[29]. The predicted three-dimensional structure of smooth-hound digestive lipase indicated the conservation of signature features such as the oxyanion hole, the lid domain, and the catalytic triad that are shared among mammalian pancreatic lipases[29]. However, the substitutions of smooth-hound lipase residues involved in binding with colipase may destabilize the lipase-colipase complex in the open conformation, potentially explaining why the classical pancreatic colipase is not efficient at activating the isolated lipase from the smooth-hound[29]. These evolutionary divergences illustrate that while the basic architecture and catalytic machinery of pancreatic lipases have remained remarkably conserved throughout vertebrate evolution, the requirement for colipase as an essential cofactor is not universal across all vertebrate lipases[29].

Clinical Implications and Therapeutic Applications

Enzyme Replacement Therapy and Pancreatic Insufficiency Management

For patients with pancreatic exocrine insufficiency due to cystic fibrosis, chronic pancreatitis, pancreatic cancer, or genetic disorders affecting colipase and lipase production, enzyme replacement therapy utilizing preparations containing both pancreatic lipase and colipase is the standard therapeutic approach[24][27][34][35]. The severe fat malabsorption and consequent deficiencies in fat-soluble vitamins (vitamins A, D, E, and K) that occur when pancreatic lipase and colipase are absent or severely reduced necessitate oral supplementation with exogenous pancreatic enzymes[27][34]. These enzyme preparations are typically derived from porcine or bovine pancreatic tissue and are designed for enteric delivery to the small intestine, where they can engage with dietary lipids[24][34][35]. The effectiveness of enzyme replacement therapy depends on delivering adequate quantities of both lipase and colipase in their proper 1:1 molar ratio to ensure optimal enzymatic activity[5][33].

Low CLPS Expression in Pancreatic Cancer

Recent molecular profiling studies have identified that low CLPS expression is associated with pancreatic cancer[46], though the precise mechanisms linking colipase expression to cancer development or progression remain to be elucidated. This association may reflect altered pancreatic acinar cell differentiation or function in malignant cells, as dedifferentiation of pancreatic acinar cells is a known step in pancreatic cancer development[46]. Whether low CLPS expression is a cause or consequence of pancreatic cancer remains an active area of investigation[46].

Conclusion and Future Perspectives

The CLPS gene encodes colipase, a remarkably sophisticated adapter protein that solves multiple fundamental problems in intestinal lipid digestion through its elegant two-surface architecture and dynamic interactions with both pancreatic lipase and dietary lipids. Rather than possessing enzymatic activity itself, colipase functions as a critical enabling factor that counteracts the inhibitory effects of bile salts, anchors pancreatic lipase to the lipid-water interface, and actively stabilizes the catalytically competent conformation of the lipase enzyme. The extensive network of five conserved disulfide bonds that characterize the colipase structure reflects millions of years of evolutionary refinement, enabling this small protein to function stably in the challenging alkaline, high-ionic-strength environment of the small intestinal lumen. The generation of enterostatin as a byproduct of procolipase activation reveals that colipase participates not merely in substrate hydrolysis but also in nutrient-sensing signaling that regulates food intake and macronutrient-specific appetite, a role that was unexpected and fundamentally changed our understanding of colipase's broader physiological significance.

The discovery that colipase function has been maintained across hundreds of millions of years of vertebrate evolution, from primitive jawless fish to modern mammals, and that colipase coevolved with the bile salt system as fundamental adaptations for efficient dietary fat absorption, underscores the biological importance of this protein for survival and reproduction. Yet this ancient and highly conserved system exhibits remarkable plasticity, as evidenced by certain fish species that have diverged from the classical colipase-dependent lipase system. Conversely, the critical dependence of mammals on the colipase-lipase system is demonstrated by the severe pathological consequences when colipase is absent or deficient, as seen in rare genetic disorders and pancreatic insufficiency states.

Future research into colipase biology promises to expand our understanding of several important areas. The precise mechanisms governing enterostatin's effects on fat-specific appetite and whether these effects can be therapeutically exploited to regulate macronutrient intake in obesity remain incompletely understood[9][12][22]. The structural details of how colipase finger-tips adapt to different lipid aggregate compositions and the role of colipase plasticity in optimizing lipase activity across the heterogeneous lipid substrate compositions encountered during digestion represent areas ripe for detailed biophysical investigation. The evolutionary basis for divergence in colipase dependence among different fish species and the specific amino acid changes responsible for colipase-independent lipase function may provide insights into protein evolution and function that have implications beyond digestion. Finally, the potential therapeutic applications of colipase and enterostatin in treating pancreatic insufficiency, improving nutrient absorption in malabsorption syndromes, or modulating appetite in metabolic disorders warrant further clinical investigation.

The remarkable biochemical elegance of the colipase-lipase system, combining specific enzyme catalysis with precise substrate targeting and regulatory signaling, exemplifies how evolution has crafted sophisticated solutions to the fundamental problem of extracting energy and nutrients from dietary macromolecules. Understanding colipase function at the molecular level not only illuminates a critical step in human nutrition but also provides a paradigm for understanding how protein-protein interactions and allosteric mechanisms enable biological complexity and metabolic adaptation.

Citations

1. https://www.genecards.org/cgi-bin/carddisp.pl?gene=CLPS
2. https://pmc.ncbi.nlm.nih.gov/articles/PMC3098174/
3. https://pmc.ncbi.nlm.nih.gov/articles/PMC6744884/
4. https://www.uniprot.org/uniprotkb/P04118/entry
5. https://taylorandfrancis.com/knowledge/Medicine_and_healthcare/Physiology/Colipase/
6. https://www.pnas.org/doi/10.1073/pnas.1414933111
7. https://www.rcsb.org/structure/1n8s
8. https://pubmed.ncbi.nlm.nih.gov/446/
9. https://pubmed.ncbi.nlm.nih.gov/8511187/
10. https://pubmed.ncbi.nlm.nih.gov/10570245/
11. https://pubmed.ncbi.nlm.nih.gov/20222694/
12. https://onlinelibrary.wiley.com/doi/abs/10.1002/j.1550-8528.1997.tb00565.x
13. https://pmc.ncbi.nlm.nih.gov/articles/PMC3996833/
14. https://pubmed.ncbi.nlm.nih.gov/2471969/
15. https://pubmed.ncbi.nlm.nih.gov/8875648/
16. https://pmc.ncbi.nlm.nih.gov/articles/PMC371277/
17. https://www.proteinatlas.org/ENSG00000137392-CLPS
18. https://www.xtal.iqfr.csic.es/publications/jbc1998.pdf
19. https://onlinelibrary.wiley.com/doi/pdf/10.1002/j.1550-8528.1997.tb00565.x
20. https://pmc.ncbi.nlm.nih.gov/articles/PMC3642234/
21. https://en.wikipedia.org/wiki/Colipase
22. https://pubmed.ncbi.nlm.nih.gov/1896501/
23. https://pmc.ncbi.nlm.nih.gov/articles/PMC4956471/
24. https://pubmed.ncbi.nlm.nih.gov/8995215/
25. https://pubmed.ncbi.nlm.nih.gov/6860687/
26. https://rarediseases.org/mondo-disease/pancreatic-triacylglycerol-lipase-deficiency/
27. https://pubmed.ncbi.nlm.nih.gov/9837944/
28. https://pmc.ncbi.nlm.nih.gov/articles/PMC7094207/
29. https://rarediseases.info.nih.gov/diseases/17402/pancreatic-colipase-deficiency
30. https://rarediseases.org/rare-diseases/johanson-blizzard-syndrome/
31. https://www.ncbi.nlm.nih.gov/books/NBK544242/
32. https://www.orpha.net/en/disease/detail/2315
33. https://pubmed.ncbi.nlm.nih.gov/1643046/
34. https://www.frontiersin.org/journals/physiology/articles/10.3389/fphys.2022.933153/full
35. https://pmc.ncbi.nlm.nih.gov/articles/PMC94915/
36. https://onlinelibrary.wiley.com/doi/abs/10.1002/9781119876007.ch8
37. https://pmc.ncbi.nlm.nih.gov/articles/PMC10269814/
38. https://www.nature.com/articles/s41598-025-01683-y
39. https://ensembl.org/id/ENST00000373861
40. https://www.genecards.org/cgi-bin/carddisp.pl?gene=CLPSL1
41. https://www.ncbi.nlm.nih.gov/gene/1208
42. http://ensembl.org/Homo_sapiens/Gene/Summary?db=core%3Bg%3DCLPSL1
43. https://www.walshmedicalmedia.com/open-access/bioinformatics-and-evolution-of-vertebrate-pancreatic-lipase-and-related-proteins-and-genes-2153-0602.1000111.pdf
44. https://pubmed.ncbi.nlm.nih.gov/7929247/
45. https://pubmed.ncbi.nlm.nih.gov/7315970/
46. https://pubmed.ncbi.nlm.nih.gov/6714581/
47. https://pmc.ncbi.nlm.nih.gov/articles/PMC5343024/
48. https://pubmed.ncbi.nlm.nih.gov/638181/
49. https://www.malacards.org/card/pancreatic_lipase_deficiency
50. https://pmc.ncbi.nlm.nih.gov/articles/PMC6314878/
51. https://pubmed.ncbi.nlm.nih.gov/7773176/
52. https://pmc.ncbi.nlm.nih.gov/articles/PMC3847720/
53. https://pubmed.ncbi.nlm.nih.gov/18506778/
54. https://core.ac.uk/download/pdf/82361861.pdf
55. the sequential theory